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The immune system is a highly-specialized cellular network that must respond to a wide 
variety of microbial species while remaining tolerant of an organism’s own cells and tissues. 
Loss of self-tolerance can lead to immune-mediated tissue destruction and disease, and 
therefore regulatory mechanisms have evolved that inhibit immune responses to self-
antigens. The work presented in this dissertation sought to better understand the biology of B 
cells that express the death-inducing molecule Fas ligand (FasL), a potentially important 
regulatory B cell population. Conceptually, FasL+ “killer” B cells are unique amongst regulatory 
B cells as they possess the potential for suppression that is both antigen-specific and 
permanent.  
The experiments herein identified a novel antagonistic relationship between the type-2 
cytokines interleukin-5 (IL-5) and IL-4 regarding their effects on FasL+ B cell function. Treating 
murine B cells with IL-5 expanded a population of B cells with potent killing activity against 
CD4+ T cells and that secreted the anti-inflammatory cytokine IL-10. In contrast, treatment 
with IL-4 inhibited both of these regulatory mechanisms in B cells. Therefore, drugs that 
activate pathways downstream of the IL-5 receptor or inhibit those downstream of the IL-4 
receptor may lead to novel areas of drug discovery for the treatment of immune-mediated 
disorders.   
Although FasL+ B cells are rare in vivo, lymphoblastoid cell lines (LCLs) generated by 
transformation of human B cells with Epstein-Barr virus (EBV) showed robust expression of 
ix 
 
intracellular FasL, suggesting that the EBV latency program in transformed B cells drives the 
production of FasL. LCLs also secreted MHCII+FasL+ exosomes that induced antigen specific 
apoptosis in CD4+ T cells in two independent experimental designs. LCLs consequently 
represent a realistic source for immuosuppressive exosomes for therapeutic use in the 
treatment of human disease. This study has therefore set the groundwork for future 














1.1 The Adaptive Immune System and Self-Tolerance 
Multicellular organisms exist in an environment teeming with microbial life, and therefore 
must possess the means to efficiently manage both harmful and innocuous microbes to 
maintain homeostasis. To accomplish this task, two central arms of the mammalian immune 
system have evolved that use distinct but complementary strategies to distinguish between 
“self” and “non-self.”  
The innate arm of the immune system, common to all vertebrates, recognizes molecular 
determinants essential to broad classes of microbes. These pathogen-associated molecular 
patterns (PAMPs) are recognized by germline-encoded receptors, allowing the innate arm to 
respond to microbes in a generic manner by recognizing common PAMPs, such as viral dsRNA 
or lipopolysaccharides of the bacterial outer membrane. Although the innate immune system 
[2] 
 
is efficient and effective, the exceptional variety and short life cycle of most microbial species 
tips the evolutionary arms race in their favor.  
In jawed vertebrates, a second arm of the immune system has evolved which acts in concert 
with the innate arm [1]. Rather than relying on the recognition of PAMPs by invariant innate 
receptors, this adaptive arm generates a highly-diversified anticipatory repertoire of adaptive 
immune receptors in lymphocytes, the main effector cells of the adaptive arm. In response to 
infection, lymphocytes bearing receptors that recognize antigens specific to the invading 
pathogen clonally expand into a pool of effector cells. Upon resolution of the infection, some 
lymphocytes become long-lived memory cells capable of responding rapidly to a secondary 
infection from the same pathogen. This strategy employed by the adaptive arm allows an 
organism to respond to an incredibly large array of antigens, and theoretically results in a 
precisely-focused immune response targeted only to pathogenic microbes rather than self-
tissues or commensal species.  
As the lymphocyte repertoire is vast and randomly-generated, however, it is all-but-inevitable 
that lymphocytes recognizing self-antigens will arise in a given organism. Some estimates 
suggest that more than half of all antigen receptors generated in vivo display some level of 
reactivity with self-antigens [2]. Lymphocytes are therefore rigorously curated, and auto-
reactive cells are deleted, anergized, or signaled to differentiate into immunosuppressive 
[3] 
 
regulatory lymphocytes (Figure 1-1). The end result of this selection process is an adaptive 
repertoire that is highly-diverse, but also self-tolerant – a state in which any aberrant immune 
response toward self-tissues is prevented from occurring or kept in check by regulatory 
mechanisms. Despite these processes, loss of self-tolerance occurs in a small but substantial 
number of people. Disorders thought to result from such breakdowns in self-tolerance are 
known as autoimmune diseases. The clinical manifestations of autoimmunity can vary greatly 
depending upon the self-antigens targeted, and although autoimmune diseases are 
individually rare, they collectively afflict more than 10 million people (1 in 31) in the United 
States [3]. The pathology associated with autoimmune diseases can be debilitating, painful, and 





Figure 1-1: Curation of the lymphocyte repertoire. 
Random rearrangement and mutation at the genetic loci encoding antigen receptors 
produces the highly-diverse anticipatory repertoire of lymphocytes, allowing the adaptive 
immune system to respond to essentially any antigen encountered. The random nature of 
rearrangement results in the production of self-reactive lymphocytes, which are either 
eliminated or inactivated through negative selection, or undergo differentiation to anti-




Therapies currently available for the treatment of autoimmune diseases act by general 
immune suppression and therefore affect protective as well as pathogenic immune responses. 
Side effects resulting from these broadly-immunosuppressive drugs include increased 
susceptibility to microbial infections and reduced cancer surveillance [4, 5]. 
Immunosuppressive drugs are expensive as well, and because most autoimmune diseases are 
chronic disorders requiring indefinite treatment, the expense of treating autoimmunity has 
become a large financial burden on the healthcare systems worldwide [6, 7]. There is therefore 
a great need for the development of therapeutic strategies for the treatment of autoimmunity 
superior to those currently available. A better understanding of how self-tolerance is 
maintained could lead to next-generation therapies that act by permanently suppressing 
responses specific to autoantigens, therefore leaving protective immune responses intact and 
eliminating the need for indefinite treatment. 
 
1.2 B Lymphocytes 
As the main effector cells of the humoral immune response, B cells are essential for host 
defense [8]. The defining feature common to all B cells is the expression of immunoglobulin, a 
glycoprotein complex comprised of two heavy chains (encoded by the IgH locus) and two light 
chains (encoded by either the Igκ or Igλ loci).  Immunoglobulins contain two structural 
[6] 
 
regions: a divalent antigen binding region, and a constant region that mediates effector 
functions. B cells express immunoglobulins either as a membrane-bound component of the B 
cell receptor (BCR), or as secreted antibodies. The antigen-binding regions of immunoglobulins 
are encoded by numerous variable (V), diversity (D), and joining (J) segments separated by 
substantial genomic distances within the immunoglobulin loci. To produce a functional 
immunoglobulin, these segments are brought together by V(D)J recombination, a process 
whereby the intervening sequences are excised from the chromosome.  As individual V, D, and 
J segments are selected stochastically and mutations from the germline sequence are 
frequently introduced during chromosome repair, this process generates extensive variability 
within the antigen-binding region. The result is an extremely diverse antibody repertoire, 
estimated in humans to be 1011 or greater [9].  
B cells perform several essential immune functions beyond antibody production as well. Most 
cells of the B cell lineage are professional antigen presenting cells (APCs), capable of 
processing and presenting exogenous antigens to CD4+ T cells via MHC class II (MHCII) 
molecules [10]. B cells preferentially activate T cells that share their antigen specificity, as 
BCR-mediated endocytosis allows them to efficiently process and present their cognate 
antigen to T cells [11, 12]. Through the secretion of polarizing cytokines, B cells can also affect 
the differentiation of T cells that they activate [13]. Therefore, B cells can directly influence T 
[7] 
 
cell-mediated immunity. Additionally, B cells can secrete an array of cytokines with local and 
systemic effects, and are essential for the proper development of lymphoid structures and 
mucosal barriers [14-16]. Because of these varied functions, B cells represent a unique and 
important functional nexus of the immune system and can influence nearly all aspects of an 
immune response. 
Extensive heterogeneity exists within the B cell population, and various subsets of B cells have 
been defined based upon the correlation of surface markers with specific functions or 
developmental stages. Delineating B cells into subsets remains a controversial topic despite 
decades of study, as few subsets show absolute correlation with a given surface phenotype [17-
19]. Despite this caveat, defining B cell subsets by this approach has proven useful in the study 
of nearly all aspects of B cell biology, and can provide important information regarding the 
lineage, stage of development, and activation status of a given B cell. 
Two main B cell lineages have been described, each with distinct functions and phenotypes 
[20, 21]. B-2 cells, the most widely-studied lineage, are responsible for the precisely-targeted 
high affinity antibodies that arise against pathogen-associated antigens during an immune 
response. A second subset of innate-like B cells produces lower affinity poly-specific antibodies 




B-2 cells   
One of the most remarkable features of the immune system is its ability to mount an antibody 
response against essentially any protein antigen, as well as other types of molecules. This feat 
is made possible by the highly-diversified anticipatory antibody repertoire generated by B-2 
cells. V(D)J recombination occurs early in B-2 cell development and generates extensive 
junctional diversity within the immunoglobulin repertoire.  This diversity is further enhanced 
by terminal deoxynucleotidyl transferase (TdT), an enzyme that adds random non-template 
nucleotides to DNA segments at the junction sites [23]. B-2 cells possessing a functional BCR 
after recombination are then screened for autoreactivity, and B-2 cells recognizing self-
antigens either undergo apoptosis, become anergic, or initiate receptor editing to produce an 
antibody that is not self-reactive [24].  
These early stages of B-2 cell development and selection occur in the bone marrow, where the 
cells of the B-2 lineage emerge from a pluripotent precursor population common to T cells and 
natural killer (NK) cells [25]. Immature B-2 cells then egress from the bone marrow into 
peripheral lymphoid organs via the blood stream [26]. B-2 cells are continuously produced 
throughout the life of an organism, as newly-differentiated cells from the bone marrow 
constantly replace dying B-2 cells in the periphery. 
[9] 
 
B-2 cells constitute the vast majority of B cells in peripheral lymphoid organs, where they 
undergo further maturation through several transitional stages [27].  Within these organs, B-2 
cells reside mostly in the lymphocyte-dense follicles where they are supported by a network of 
follicular dendritic cells (FDC). The FDC network helps to capture and concentrate antigens 
from draining lymph or blood [28]. The follicle therefore represents a unique anatomical niche 
that increases interaction between B-2 cells and potential antigens.  
Upon encountering their cognate antigen, B-2 cells within the follicle become activated and 
proliferate; this growing region of proliferating antigen-specific B-2 cells grows into a dynamic 
structure known as a germinal center [29]. Reciprocal interaction with CD4+ T helper (TH) cells 
occurs within germinal centers, as B-2 cells present antigen to follicular T cells which in turn 
provide survival and activation signals to B-2 cells. While germinal centers are initially 
pauciclonal, the repertoire within the germinal center is diversified by somatic hypermutation 
of the immunoglobulin loci [30]. Among hypermutated B-2 cells, those with higher affinity 
BCRs are more efficient at processing and presenting antigen, and therefore have an advantage 
in soliciting help from follicular T cells. As the germinal center reaction progresses, this 
selective pressure produces a pool of B-2 cells producing antibodies with progressively higher 
affinities [31]. Thus, the germinal center provides an environment which drives the emergence 
of B-2 cells producing antibodies with very high affinity for the cognate antigen. Cytokines 
[10] 
 
within the follicular microenvironment signal B-2 cells to undergo isotype switching, making 
B-2 cell-derived antibodies functionally diverse [32].  
While the fate of most B-2 cells is to undergo apoptosis as the germinal center recedes, some 
germinal center B-2 cells will differentiate further. Plasma cells leave the germinal center and 
move to the bone marrow or the lamina propria of mucosa, where they secrete large amounts 
of high-affinity antibody.  Some plasma cells can persist for long periods of time, providing 
continuous levels of protective antibodies. Other germinal center B-2 cells differentiate into 
memory B cells, which maintain surface immunoglobulin expression while secreting relatively 
small amounts of antibody.  Memory B cells are long-lived and respond rapidly to future 
encounters from the same pathogen [33]. 
Innate-like B cells 
According to the layered immune system hypothesis, cell populations arise evolutionarily and 
ontologically in order of increasing complexity [34]. Innate-like B cells, a subset comprised of 
B-1 cells and marginal zone (MZ) B cells, are thought to be the more primitive of the B cell 
layers and maintain some features of an ancestral B cell population [22]. Although their 
antibody response lacks much of the complexity of that of B-2 cells, innate-like B cells serve 
important non-redundant functions in host defense. 
[11] 
 
The first functional B cells to emerge during development, innate-like B cells arise before birth 
from a precursor population that emigrates from the bone marrow to the fetal liver [35]. 
Whereas the B-2 cell population requires constant replenishment, innate-like B cells develop 
early in life and persist into adulthood by self-renewal, with little replacement from the bone 
marrow [36]. Antibodies produced by innate-like B cells are secreted in the absence of 
antigenic stimulation and are therefore commonly referred to as “natural” antibodies. 
Production of natural antibodies begins before birth and is constitutive, and therefore natural 
antibodies provide a baseline level of antibody-mediated protection even in the absence of 
infection [37]. Innate-like B cells are found almost exclusively at sentinel locations within the 
body, with B-1 cells concentrating in tissues associated with mucosal barriers, and MZ B cells 
monitoring the contents of the blood stream in the marginal zone of the spleen. In these 
locations, innate-like B cells act as a “front-line” defense against pathogens, as they can 
rapidly respond to an infection by increasing their antibody production and releasing 
inflammatory cytokines. These functions help to limit microbial growth in the early stages of 
an infection before a full adaptive immune response can be generated. 
Whereas the antibody repertoire of B-2 cells is vast, that of innate-like B cells is restricted and 
semi-invariant. Although the immunoglobulin loci of innate-like B cells undergo 
recombination, the recombined sequences are mostly unaltered from those found in the 
[12] 
 
germline and are restricted in their VH gene usage. Antibodies secreted by innate-like B cells 
are frequently poly-reactive, binding many structurally-unrelated antigens with low affinity. 
This broad specificity makes natural antibodies effective in defense from a wide range of 
bacterial and viral pathogens [38-40]. Although MZ B cells play a role in shuttling antigens 
from the blood to follicles in the spleen, it is thought that innate-like B cells themselves do not 
participate in germinal center reactions nor undergo somatic hypermutation or affinity 
maturation [41, 42]. Therefore, while the repertoire of B-2 cells adapts in real time to produce 
antibodies against a specific pathogen, that of innate-like B cells is far less dynamic and has 
been selected over evolutionary time scales for broad specificity. 
In addition to their broad reactivity with pathogen-associated antigens, natural antibodies 
frequently bind self-antigens as well. Prominent among the self-antigens bound by natural 
antibodies are apoptosis-associated determinants and oxidized lipids. These natural 
autoantibodies are thought to be adaptive rather than a consequence of incomplete negative 
selection, as innate-like B cells undergo a positive selection event based upon their reactivity 
with self-antigens [43, 44]. The function of these self-reactive natural antibodies will be 





1.3 B cell Functions in the Pathogenesis of Autoimmune Disease 
Autoimmune diseases are frequently associated with aberrant responses from both the 
humoral and cellular compartments, suggesting that both B cells and T cells play important 
roles in these diseases. For a variety of reasons, however, considerably more resources have 
gone toward the study of T cells in autoimmunity, especially in regard to so-called “T cell-
mediated” diseases such as rheumatoid arthritis (RA), type 1 diabetes (T1D), and multiple 
sclerosis (MS). The incidence of many autoimmune diseases is strongly linked with specific 
human leukocyte antigen (HLA) class II haplotypes, suggesting that the nature of the CD4+ T 
cell receptor repertoire is critical for the initiation of autoimmunity. In several animal disease 
models, adoptive transfer of activated antigen-specific T cells is sufficient to induce 
autoimmunity in recipient animals, and T cells are frequently found in inflamed organs such 
the synovium of RA patients [45-47]. T cells were therefore thought to be central to 
autoimmune pathogenesis, with B cells playing a secondary or indirect role in disease. 
Over the past two decades, however, strong evidence has accumulated demonstrating that B 
cells are crucial players in the pathogenesis of many autoimmune disorders as well. In mice, 
the absence or depletion of B cells is protective in CD4+ T cell-mediated autoimmune disease 
[48]. Production of the cytokine TNFα is a key contributor to inflammation in RA, and IgG 
immune complexes can drive TNFα production by binding to activating Fc receptors on 
[14] 
 
monocytes [49, 50]. These observations prompted clinical studies assessing the efficacy of B 
cell-depletion therapy in the treatment of autoimmunity in humans. The first such therapeutic 
to achieve approval was rituximab, a chimeric anti-CD20 antibody initially developed to treat B 
cell-derived lymphomas [51, 52]. Rituximab has achieved clinical success in the treatment of 
RA and some forms of vasculitis [51-55]. The efficacy of rituximab inspired a surge in research 
focusing on B cells in autoimmunity, and several other drugs targeting B cell functions have 
recently achieved approval or are the subject of ongoing clinical trials. The results of these 
studies have led to a greater appreciation for the complex role B cells have in autoimmunity, 
and it is now recognized that targeting the function of B cells can be a powerful therapeutic 
strategy. 
Autoantibodies in Autoimmune Diseases 
A hallmark feature of many autoimmune disorders is the presence of antibodies that bind to 
self-antigens. Autoantibodies against a wide variety of self-antigens have been described, 
including those targeting soluble proteins, intracellular and nuclear antigens, cell surface 
molecules, and components of the extra cellular matrix. The clinical effects of autoantibodies 
are generally a product of both the specific self-antigen recognized by the autoantibody, and 
its isotype.    
[15] 
 
Antibodies against self-antigens can mediate pathology by targeting an immune response 
toward self-antigens, often with devastating consequences. During a normal immune response, 
antibodies serve to identify invading pathogens and promote inflammation at the site of 
infection. Clearing the pathogen removes any antigen, and therefore antibodies no longer 
accumulate at the site of infection and inflammation subsides. Antibodies against self-antigens 
accumulate in locations with an abundance of self-antigen, leading to chronic inflammation 
and subsequent tissue damage. Autoantibodies are most commonly found as either IgM or IgG 
isotypes, both of which are capable of fixing complement [56]. Products of the complement 
cascade stimulate the release of pro-inflammatory cytokines and leukotrienes in local immune 
cells, and promote the recruitment of circulating effector cells. Autoantibodies also promote 
inflammation by binding to activating Fc receptors, as IgG autoantibodies binding to Fc 
receptors induces secretion of pro-inflammatory cytokines [49, 57]. Injection of autoantibodies 
is sufficient to induce onset of disease in some mouse models of autoimmunity, demonstrating 
that autoantibodies are capable of initiating immune-mediated tissue damage [58-60]. This 
ability of autoantibodies to induce inflammation is essential in the pathogenesis of collagen-
induced arthritis, as mice lacking activating Fcγ receptors or the complement component C5 
are resistant to disease despite high levels of circulating autoantibodies [61, 62]. 
[16] 
 
Autoantibodies reactive against soluble self-antigens result in the formation of immune 
complexes in circulation. In the case of an abundant self-antigen, the rate of immune complex 
formation can overwhelm existing clearance mechanisms, leading to chronically high immune 
complex levels. Immune complexes are more likely to deposit in certain locations of the body 
and therefore accumulate in places such as small blood vessels and joints. This local buildup 
promotes inflammation, and the subsequent recruitment and activation of immune cells can 
result in substantial tissue damage. This mechanism is especially important in the 
pathogenesis of systemic lupus erythematosus (SLE), where immune complexes tend to 
accumulate in the blood vessels within glomeruli [63]. Over time, tissue damage resulting from 
this deposition can result in renal failure and death. 
Complement-fixing autoantibodies recognizing cell surface antigens can promote the 
deposition of the membrane-attack complex on targeted cells. While most cells are resistant to 
lysis mediated by the membrane-attack complex, others can be depleted by this mechanism. 
Examples of such disorders include autoimmune thrombocytopenia and hemolytic anemia, 
diseases which are mediated by autoantibodies recognizing surface structures on platelets and 
erythrocytes, respectively [64, 65].  
In some autoimmune disorders, autoantibodies mediate pathology independently of 
inflammation by binding to and modulating the activity of their target molecule. In Grave’s 
[17] 
 
disease, autoantibodies activate the thyroid-stimulating hormone (TSH) receptor [66]. As a 
consequence, thyroid hormones are produced in excess, resulting in hyperthyroidism. 
Autoantibodies that inactivate acetylcholine receptors are thought to be responsible for 
development of myasthenia gravis, a potentially-fatal neuromuscular disorder [67]. In some 
patients with RA, autoantibodies that bind to and activate peptidylarginine deiminases (PADs) 
can be found [68]. PADs produce citrullinated proteins, a critical autoantigen in RA, and 
therefore PAD-activating autoantibodies may help to drive inflammation in RA by generating 
citrullinated autoantigens [68]. Disorders caused by antibodies against cytokines such as IFNγ, 
IL-6, and members of the IL-17 family have been identified as well, frequently resulting in 
impaired immune defense against specific types of microbes [69-71].   
Antibody-Independent B cell Functions in Autoimmunity 
There is strong evidence that the role of B cells in autoimmune disease extends beyond the 
production of autoantibodies. Rituximab, the most frequently-used B cell depletion therapy, 
does not deplete antibody-secreting plasma cells [72]. While a significant decline in 
autoantibody levels occurs after administration of rituximab, this decrease does not 
necessarily correlate with response to treatment in RA patients, and clinical improvement 
frequently precedes this reduction in autoantibody levels [73-75]. Additionally, although 
rituximab treatment is effective in treating MS, a drug targeting both B cells and plasma cells 
[18] 
 
exacerbated rather than alleviated symptoms in MS patients [76-78]. In a mouse model of SLE, 
mice with B cells incapable of secreting antibody still develop symptoms of nephritis [79]. 
These observations suggest that antibody-independent B cell functions are crucial in the 
propagation of autoimmune disease.  
The reciprocal interaction between T cells and B cells is central to most adaptive immune 
responses, and as a consequence each is capable of modulating the activity of the other. B cells 
use BCR-mediated endocytosis to process and present their cognate antigen to CD4+ T cells, 
preferentially activating T cells that share their specificity. An autoreactive B cell can 
therefore process and present self-antigens to T cells, thus driving autoimmunity in the 
cellular compartment. Importantly, although B cells recognize a specific epitope of a given 
antigen, the entirety of the antigen is endocytosed and processed for antigen presentation.  As 
a result, B cells recognizing self-antigens present multiple epitopes to T cells, triggering 
diverse T cell responses to a single self-antigen [80]. Known as “epitope spreading,” this 
phenomenon allows an autoimmune response to spread to targets other than the initial 
epitope as disease progresses [81]. This progressive diversification of the response to self-
antigens is a feature common to many autoimmune diseases and usually correlates with 
increased severity of symptoms [82]. In some cases, epitope spreading can occur between two 
molecules if antigens are physically linked [83, 84].  
[19] 
 
B cells can also influence a cellular immune response by the secretion of T cell polarizing 
cytokines. In experimental autoimmune encephalomyelitis (EAE), B cells were found to be the 
major producer of IL-6, a cytokine important for the function of TH17 cells [85].  Additionally, 
while B cell depletion effectively treated disease in wild-type mice, depletion was ineffective in 
mice lacking IL-6 expression in B cells, suggesting that the therapeutic effect of B cell depletion 
was mediated by the loss of IL-6-expressing B cells [85]. Data from human subjects support this 
idea, as B cells from human patients with MS produced more IL-6 than healthy controls as well 
[85]. Remarkably, treatment of these patients with rituximab essentially “reset” their 
peripheral B cells, as those returning after depletion secreted IL-6 at levels equivalent to those 
of healthy controls [85]. The loss of IL-6-expressing B cells in both mice and human patients 
was associated with a reduction in TH17 activity, suggesting that IL-6-expressing B cells are 
capable of inducing pathogenic TH17 responses [85]. B cells capable of specifically supporting 
the production of either TH1 or TH2 cells have been identified as well, named B effector 1 (Be1) 
and B effector 2 (Be2) cells, respectively [13]. While these effector B cell subsets can skew a T 
cell response by secretion of polarizing cytokines, the importance of these cell types in 
autoimmunity has not thus far been evaluated. 
B cells are frequently found at sites of autoimmune inflammation, such as the synovium of RA 
patients, the central nervous system of patients with MS, and the thyroid of some patients 
[20] 
 
with autoimmune thyroid disease [86-88]. In some cases, highly-organized lymphoid-like 
structures resembling follicles and germinal centers can be identified at these sites. In RA, the 
presence of ectopic germinal centers is associated with higher expression of inflammatory 
cytokines [89]. While there is some evidence that B cells within these ectopic germinal centers 
can undergo affinity maturation, their role in the production of high-affinity autoantibodies is 
still controversial [90]. The presence of B cells in the synovium, however, appears to be crucial 
to maintaining T cell activation, as the depletion of B cells significantly reduced T cell 
production of inflammatory cytokines in human synovium/severe combined 
immunodeficiency (SCID) mouse chimeras [91]. Synovial B cells have been reported to express 
a wide variety of inflammatory cytokines as well, including TNFα, IL-1α, IL-6, IL-12, and RANKL 
[92]. B cells therefore have multiple crucial roles in maintaining inflammation at sites of 
autoimmune attack. 
 
1.4 Regulatory B cell Functions in Inflammatory Conditions 
Although evidence for the existence of anti-inflammatory “regulatory” B cells was first 
reported almost 40 years ago, their immunosuppressive function has received significant 
attention only in the last 15 years [93]. Despite this, there is now clear evidence that B cells can 
modulate disease in many mouse models of autoimmune diseases, including MS [94, 95], 
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chronic intestinal inflammation [96], T1D [97, 98], SLE [99, 100], and RA [101]. B cells can 
mediate immune suppression through a variety of mechanisms, some of which are unique to B 
cells [102]. The major mechanisms of B cell-mediated immune suppression are discussed 
below. 
Sialylated IgG 
Despite the clear role of IgG in pathogen clearance, it has been known for decades that high 
doses of intravenous immunoglobulin (IVIg) therapy has an anti-inflammatory effect, and IVIg 
is now commonly administered to patients with inflammatory disorders such as idiopathic 
thrombocytopenic purpura [103, 104]. The high dose required for anti-inflammatory effects, 
however, suggested that only a minor fraction of IgG molecules possessed anti-inflammatory 
activity, and indeed a minor glycoform of IgG with terminal sialic acid additions has been 
identified that mediates anti-inflammatory effects at much lower doses [105]. Removing sialic 
acid residues from IVIg preparations severely reduced their immunosuppressive function, 
suggesting that sialylated IgG is the anti-inflammatory component of IVIg [105].  
A  family of Fcγ receptors are expressed on cells of both the innate and adaptive immune 
system that modulate the activity of a cell in response to binding IgG [106]. Both activating and 
inhibitory receptors exist within the Fcγ receptor family, and their relative levels of 
expression determine the activation threshold for a given cell [106]. The Fc portion of IgG 
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contains a single biantennary N-linked glycan that is required for binding Fcγ receptors, and 
whereas all IgG molecules appear to have a core heptasaccharide moiety comprised of N-
acetlylglucosamine (GlcNAc) and mannose at this site, more than 30 alternative glycoforms 
have been identified on naturally-occurring IgG molecules [107]. Relative to other glycoforms, 
sialylated IgG has reduced affinity for classical Fcγ receptors and increased ability to bind to an 
alternate C-type lectin receptor, SIGN-R1 [108]. 
Sialylated IgG mediates immune suppression through a novel innate immunosuppressive 
pathway using TH2-related cytokines [108]. Splenic macrophages and dendritic cells expressing 
SIGN-R1 (or the human ortholog DC-SIGN) respond to Sialylated IgG by secreting IL-33, which 
in turn increases the number of circulating IL-4-producing basophils [109]. IL-4 produced by 
these activated basophils then acts on  effector macrophages in the periphery, causing them to 
up-regulate the inhibitory FcγRIIB receptor and thus increasing the activation threshold of 
these cells and down-regulating their pro-inflammatory capacity [58].   
IgG sialylation status may be an important factor in the pathogenesis or disease course of 
autoimmunity.  Rheumatoid arthritis is associated with a decrease in galactosylated and 
sialylated serum IgG [107]. Additionally, it has been shown that autoantigen-specific IgG 
displays reduced sialylation, and this reduction was more pronounced at the site of active 
inflammation [110]. Despite this, remarkably little is known about signals that modulate the 
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glycosylation status of secreted antibodies. It appears that an active inflammatory response 
reduces the relative amount of sialylated IgG, although no mechanism for this reduction is 
currently known [105]. A recent study characterized the glycan profile of IgG secreted from 
human primary B cells in response to various pro-inflammatory cytokines and innate stimuli 
[111]. Somewhat surprisingly, it was found that many stimuli tested [including IL-4, IL-6, IL-17, 
TNFα, TGFβ, and LTα] had no measurable effect on IgG sialylation. Even more intriguingly, 
those pro-inflammatory stimuli that did have an effect [CpG, IL-21, IFN-γ, and all-trans retinoic 
acid) actually increased levels of sialylation and galactosylation rather than decreasing them. 
The phenotype or anatomic location of the B cells that secrete sialylated IgG is currently 
unknown. MZ B cells, however, may play a role in pathways downstream of sialylated IgG, as 
macrophages in the marginal zone do not express SIGN-R1 in mice lacking MZ B cells, and 
SIGN-R1+ macrophages transiently exit the marginal zone when MZ B cells are stimulated to do 
so  [112].  
Natural Antibodies 
Natural antibodies secreted by innate-like B cells have multiple roles in maintaining immune 
homeostasis. Among these is aiding in the elimination of apoptotic cells, a key function of the 
immune system [113]. If this process is inhibited or overwhelmed, apoptotic cells are not 
removed before their plasma membrane loses integrity, resulting in the release of self-
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antigens and inflammatory signals into the interstitial space. This in turn can lead to increased 
tissue destruction and induction or exacerbation of autoimmunity. The surface phenotype of 
cells undergoing apoptosis is altered from that of healthy cells by the presence of apoptosis-
specific neo-epitopes, sometimes referred to as “eat-me” signals [114]. Apoptotic cells display 
“eat-me” signals on their cell surface, such as an enrichment of lipids containing 
phosphorylcholine [PC] or malondialdehyde [MDA]. The antibody repertoire of innate-like B 
cells is enriched for antibodies that bind these apoptosis-induced determinants, and their 
binding to apoptotic cells aids in their engulfment by phagocytic cells [115]. Natural antibodies 
also directly regulate the inflammatory capacity of APCs directly by inhibiting their 
maturation and reducing their expression of molecules involved in antigen presentation [116]. 
The administration of a model natural antibody in vivo has a general immunosuppressive 
effect, as mice receiving the antibody are protected from both collagen-induced arthritis and a 
passive transfer model of arthritis induced by anti-collagen IgG antibodies [116]. In addition to 
apoptotic cells, the lipid epitopes bound by natural antibodies are also found on the surface of 
bacteria such as S. pneumoniae and within oxidized LDL deposits found in atherosclerotic 
lesions [114]. In mouse models of atherosclerosis, natural antibodies reduce the severity of 
disease, and increasing levels of anti-PC natural antibodies by immunization led to a decrease 
in atherosclerotic lesion formation [117].  
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Circulating levels of natural antibodies are increased in mice that have received either large 
doses of apoptotic cells or have been immunized with pneumococcal extracts, suggesting that 
the presence of cognate antigen determines the level of natural antibody secretion. In some 
cases natural antibody responses to different antigens are coordinately regulated, as 
immunization with one B-1 cell-specific antigen, malondialdehyde-modified low density 
lipoprotein (MDA-LDL), resulted in an increase in natural antibodies recognizing another B-1 
cell-specific antigen, phosphorylcholine [114].  Finally, T cell responses in mice immunized 
with natural antibody-binding antigens are dominated by the TH2-type response even if the 
antigen is administered with TH1-skewing adjuvant, suggesting that the selective expansion of 
TH2 cells may be another regulatory mechanism of natural antibodies [117].  
IL-10-secreting B cells 
The most widely-studied and best-understood immunosuppressive mechanism in B cells is the 
secretion of IL-10, an important anti-inflammatory cytokine [118]. IL-10 has multifaceted 
effects on nearly all hematopoietic cells, but appears to act most directly on APCs and some T 
cell subsets [119]. In APCs, IL-10 inhibits the secretion of pro-inflammatory cytokines and 
inhibits antigen presentation [120-124]. IL-10 directly affects differentiated CD4+ T cells as 
demonstrated in studies in which both TH1 and TH2 cells exhibited reduced proliferation and 
cytokine secretion in the presence of IL-10 [125, 126].  
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Although B cells had been known to secrete IL-10 for some time, only recently has the 
importance of B cell-derived IL-10 in immunosuppression been demonstrated definitively [95, 
96, 127, 128]. A subset of IL-10-producing B cells in the gut-associated lymphoid tissue [GALT] 
was identified in 2002. These IL-10-producing B cells mediated suppression of intestinal 
inflammation in recipient animals upon transfer [96].  In the same year, a role for IL-10-
producing splenic B cells in the regulation of autoimmunity was reported [95]. Subsequent 
work has demonstrated that B cell-derived IL-10 regulates autoimmunity in various other 
mouse models of autoimmune conditions including chronic intestinal inflammation, collagen-
induced arthritis, T1D, and SLE [96, 97, 99-101]. Mice prone to spontaneous autoimmunity 
[NZB/W, NOD, and MRL/lpr mice] have increased numbers of IL-10-producing B cells relative 
to normal strains, whereas mice susceptible to induced autoimmunity [DBA/1, SJL] have lower 
basal numbers of IL-10-producing cells [129].  
Splenic IL-10-producing B cells were initially reported to have a surface phenotype consistent 
with transitional 2-marginal zone precursor [T2-MZP] B cells, namely high expression of CD21, 
CD23, and IgM [130]. Later, a portion of splenic IL-10-producing B cells were shown to co-
express CD5 and CD1d in addition to the previously described T2-MZP B cell markers, and 
CD19+CD5+CD1dhigh B cells were found to have IL-10-dependent immunosuppressive properties 
upon transfer into recipient animals [131]. More recently, the protein TIM-1 was reported to 
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identify 70% of IL-10-producing B cells, making this marker the most specific yet identified for 
IL-10-producing B cells [132]. Treatment of mice with an activating anti-TIM-1 antibody led to 
an increase in IL-10-producing TIM-1+ B cells and improved tolerance of an allogeneic tissue 
graft, suggesting that TIM-1 is of functional significance for IL-10-producing B cells as well.  
Much controversy still exists regarding the relationship of IL-10-producing B cells to known B 
cell subsets. While IL-10-producing B cells are enriched in the T2-MZP and CD5+CD1dhi subsets, 
not all cells in these subsets express IL-10, suggesting that there is not an absolute 
correspondence between these B cell subsets and IL-10-producing B cells. The fact that many 
IL-10-producing B cells express CD5 suggests that they may also be related to the innate-like B 
cells, which is in accord with the known ability of B-1a cells to secrete large amounts of IL-10 
[127]. Additionally, splenic IL-10-producing B cells are present at much higher frequencies in 
neonates than in older mice as is also true of B-1 cells [129]. Finally, while the CD5+CD1dhi B cell 
population is enriched for IL-10-producing B cells, only ~25% of IL-10-producing B cells are 
found in this population. Indeed, IL-10-producing B cells can be found among most major 
subsets of splenic B cells, albeit at a lower frequency than is seen among CD5+CD1dhigh B cells. 
Given that no set of surface markers identifies all IL-10-producing B cells, it is also possible that 
IL-10 production occurs in several B cell subsets depending upon differentiation or activation 
state.   
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While it is clear that IL-10 plays a major role in B cell-mediated immune suppression, it is not 
currently known if B cell-derived IL-10 acts exclusively on target cells or if the loss of IL-10 in B 
cells also leads to defects in other immunosuppressive functions. This is an important area of 
study, as IL-10 is a known growth factor for B cells and other suppressive mechanisms 
employed by B cells may work in synergy with IL-10 [133].  
Fas Ligand-expressing Killer B cells 
Interaction between Fas ligand (FasL) and its receptor Fas is critical for the maintenance of 
self-tolerance, as mice deficient in either of these molecules develop spontaneous systemic 
autoimmunity [134, 135]. Similarly, defects in Fas-mediated apoptosis are linked to 
autoimmune lymphoproliferative syndrome (ALPS) in humans [136]. Upon binding the Fas 
receptor (CD95), FasL induces apoptosis in target cells such as activated peripheral CD4+ T cells 
[137].  
B cells expressing FasL were initially reported following stimulation of murine B cells with 
mitogens [138]. Subsequently, several groups have reported FasL expression in B cells under a 
variety of conditions. Some forms of B cell-derived cancers in humans have been reported to 
express FasL, including multiple myeloma, B cell chronic lymphocytic leukemia, and large B 
cell lymphoma [139-141]. Expression of FasL by B cell-derived cancers is associated with 
increased T cell apoptosis [139, 140]. Viral infections have been reported to induce FasL 
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expression in B cells as well, and this has been proposed as mechanism of immune evasion 
employed by some viruses [142-144]. FasL-expressing B cells were induced by infection with 
the parasitic worm S. mansoni in mice, and their increased frequency coincided with greater 
levels of apoptosis in CD4+ T cells [145]. Later, it was demonstrated that CD5+ B cells isolated 
from schistosome infected mice could induce apoptosis in T cells, whereas CD5- B cells showed 
little killing activity [146]. 
There is also evidence that FasL-expressing B cells may play a role in the regulation of 
autoimmunity and maintaining self-tolerance. Activated B cells expressing FasL and TGFβ have 
been reported to delay the onset of diabetes in non-obese diabetic (NOD) mice, and the 
frequency of FasL+ B cells is reduced in mice with severe autoimmune arthritis relative to those 
with mild or no arthritis [98, 147]. Mice with a B cell-specific loss of FasL spontaneously 
develop autoantibodies despite the fact that T cells in these animals are FasL-sufficient, 
demonstrating that B cell expression of FasL plays a role in maintaining immune homeostasis 
[148]. Bone marrow cells treated with the TLR-9 agonist CpG are enriched for B cells that 
express high levels of FasL and protect NOD mice from type 1 diabetes upon adoptive transfer 
[149]. Additionally, these CpG-elicited FasL+ B cells induced FasL-mediated apoptosis in CD4+ T 
cells in vitro and showed no evidence of increased IL-10 secretion [149]. B cells from Fas-
deficient MRL/lpr mice also express high levels of FasL, and kill Fas-susceptible target cells 
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with an efficiency similar to that of NK cells [150].  In a male-to-female skin graft model, 
transfer of B cells from wild-type males prior to skin grafting induced tolerance in female 
recipients, whereas FasL-deficient B cells were unable to transfer tolerance [151]. 
Conceptually, FasL+ B cells are unique amongst regulatory B cell populations as they possess 
the potential for suppression that is both antigen specific, since only CD4+ T cells recognizing 
antigens presented by FasL+ B cells are targeted, and permanent, as FasL signaling results in cell 






Figure 1-2: Model of killer B cell function.  
In our model of killer B cells, antigens are taken up and concentrated in the secretory 
lysosome through BCR-mediated endocytosis. MHCII molecules loaded with the antigen are 
expressed at the surface along with FasL. CD4+ T cells recognizing the antigen are then 




1.5 Fas Ligand Function and Regulation 
FasL (CD178) and its receptor Fas (CD95) are transmembrane proteins and members of the 
tumor necrosis factor (TNF) and TNF receptor superfamilies, respectively. Mutations in the 
genes coding for either Fas or FasL in humans can result in autoimmune lymphoproliferative 
syndrome, a monogenic disease characterized by lymphadenopathy, splenomegaly, and 
autoimmune disease [136]. Mice bearing similar mutations develop a homologous disorder that 
presents with lymphadenopathy, production of autoantibodies, and age-related lupus-like 
symptoms [134, 135]. Therefore, the Fas/FasL signaling axis is critical for maintaining immune 
homeostasis and self-tolerance. 
FasL is the only known ligand for the pro-apoptotic surface receptor Fas, and as a potent 
inducer of apoptosis its expression is restricted to a few cell types and is highly regulated. [153, 
154]  In locations of immune privilege (e.g., eyes, testes), several cell types constitutively 
express FasL mRNA and display FasL protein on their plasma membrane to eliminate any 
immune cells that may enter their compartment.  In contrast, FasL expression and trafficking 
is inducible in NK cells and CD8+ cytotoxic T cells (CTLs), as these cells sequester FasL 
intracellularly and translocate it to the immunological synapse only upon contact with a target 
cell [155, 156].  FasL, like other TNF-related ligands, functions as a homotrimer.  Once on the 
surface of cells, the extracellular portion of FasL is cleaved by metalloproteases and the soluble 
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form of FasL is released [157].  This soluble form, however, is relatively unstable in trimeric 
form and therefore shows greatly-diminished apoptosis-inducing activity.  After cleavage of 
the extracellular portion, the intracellular portion is also released from the membrane and 
translocates to the nucleus [158]. The functional consequences of this nuclear translocation 
are currently unknown.  
The main function of Fas/FasL signaling is the induction of apoptosis in the Fas-bearing cell 
[137]. Upon binding FasL, Fas recruits the adapter Fas-associated protein with death domain 
(FADD), which in turn recruits caspase-8 (FLICE) to the receptor complex to form the death-
inducing signaling complex (DISC). Autocatalysis activates and releases caspase-8 to cleave and 
activate effector caspases, ultimately resulting in cell death. This pathway is inhibited by 
cellular FLICE-like inhibitory protein (cFLIP), an inactive caspase-8 analog that competes with 
caspase-8 for incorporation in the DISC. An alternative pathway downstream of the DISC exists 
in some cell types whereby the pro-apoptotic molecule Bid is activated by caspase-8 [159]. 
Once activated, Bid initiates the release of cytochrome c from mitochondria, allowing 
activation of caspase-9 through formation of the apoptosome. Activated caspase-9 can then 
initiate apoptosis by activating effector caspases such as caspase-3. 
T cells are thought to be the most important in vivo targets for FasL-mediated killing, as the 
transfer of Fas-deficient T cells from lpr mice into wild type animals is sufficient to induce 
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lymphoproliferative symptoms in recipients [160]. Fas is found in abundance on the surface of 
activated CD4+ T cells, and most thymocytes [137]. Despite high expression in thymocytes, Fas-
mediated cell death does not appear to be important for negative selection [161]. 
Nearly all studies of FasL transcription and trafficking in hematopoietic cells have been 
performed using CTLs, so very little is known about the regulation of FasL in B cells.  Through 
this work in CTLs, FasL expression is known to be controlled by a variety of transcription 
factors [154, 162]. In T cells, signaling through the TCR leads to transcription of FasL via several 
parallel pathways, including calcineurin-mediated activation of the NFAT family of 
transcription factors, PKCƟ-mediated activation of NF-kB, and MAPK pathway-mediated 
activation of the AP-1 transcription factor complex [162].  Additionally, interferon regulatory 
factors (IRFs), transcription factors that induce the production of interferons in response to 
viral detection, appear to synergize with TCR-mediated signaling to increase FasL expression 
in CTLs [163]. Post-transcriptional regulation of FasL has been reported as well, specifically in 
the form of AKT-mediated up-regulation of miR-21, which appears to directly target the 3’UTR 
of FasL mRNA [164]. 
In hematopoietic cells, however, post-translational regulation appears to be the most 
important level of organization for proper function of FasL.  In the absence of post-
translational modifications, FasL is sorted through the Golgi to the plasma membrane [165].  In 
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hematopoietic cells, however, FasL is sorted via phosphorylation and mono-ubiquitylation to 
an intracellular structure known as the secretory lysosome (SL) [165]. The SL is functionally 
and morphologically similar to multi-vesicular bodies (MVBs) of the late endosome, and serves 
as a point of intersection between the endocytic and exocytic pathways.  In this compartment 
FasL is sorted on to intraluminal vesicles within the limiting membrane of the SL known as 
exosomes [166].  When the limiting membrane fuses with the plasma membrane during 
exocytosis, the FasL-bearing exosomes are expelled into the extracellular space.  This allows 
for FasL to be released in its membrane-bound form which displays much greater efficacy in 
inducing apoptosis than the soluble form shed from the plasma membrane.  
 
1.6 Exosomes and Immune Regulation 
Exosomes are extracellular vesicles approximately 50-90nm in diameter that are secreted by a 
variety of immune cells and cell lines. In APCs exosomes originate from the same intracellular 
compartment where newly-synthesized and recycled MHCII molecules are loaded with 
peptides derived from endocytosed proteins [167]. Exosomes derived from APCs therefore 
contain peptide-loaded MHCII and co-stimulatory molecules, and are capable of activating 
antigen-specific T cells [167]. Unlike other types of APCs, B cells can target antigens to their SL 
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via BCR-mediated endocytosis, thus allowing them to more efficiently load their cognate 
antigen in MHCII molecules bound to exosomes [168]. 
The existence of immunosuppressive APC-derived exosomes has been established as well.  
Stimulation of murine bone marrow-derived dendritic cells (BMDCs) with rIL10 resulted in the 
production of exosomes capable of suppressing an immune response in vivo [169]. Additionally, 
BMDCs transfected with a vector expressing the FasL gene produced MHCII+FasL+ exosomes 
that were able to suppress an immune response in vivo [170].  Importantly, the suppression 
mediated by the MHCII+FasL+ exosomes was antigen-specific and FasL-dependent.  Later, 
naturally-occurring MHCII+FasL+ exosomes were isolated from the blood of immunized mice, 
confirming the production of MHCII+FasL+ exosomes by non-transformed cells [171].  These 
endogenously-produced MHCII+FasL+ exosomes also demonstrated antigen-specific immune 
suppression upon transfer to recipient mice.  Currently the cell type responsible for producing 
MHCII+FasL+ exosomes remains unclear, although based upon the presence of CD11b, 









Interleukin-5 supports the expansion of FasL-expressing B cells that induce  




The experiments described in this chapter were performed with the goal of identifying factors 
important for the growth or function of FasL+ killer B cells.  To this end, we initially sought to 
better characterize the surface phenotype of splenic FasL+ B cells, hypothesizing that this 
knowledge might provide insight into their biology. Although work from our laboratory had 
previously demonstrated that FasL+ B cells were CD5+, a more thorough analysis was required 
to determine the relationship of FasL+ B cells to various known subsets of B cells, including at 
least two IL-10-producing B cells identified by others [130, 131, 146, 147]. The results of these 
experiments showed that FasL+ B cells shared some phenotypic characteristics with the so-
called “B10” subset – a population of IL-10-producing B cells first identified by the Tedder 
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laboratory [131].  Given these similarities, we attempted to determine the degree of overlap 
between FasL+ B cells and IL-10-producing B cells. Although we did identify a very rare 
population of FasL+IL-10+ B cells, IL-10 production was not more common among FasL+ B cells 
than FasL- B cells despite their shared enrichment in a common B cell subset.  
Following this phenotypic characterization, we analyzed global mRNA expression in a subset of 
B cells that is enriched for both FasL+ B cells and IL-10-producing B cells by microarray. The 
results of this microarray showed that two components of the IL-5 receptor were expressed at 
higher levels in the B cell population enriched for regulatory cells, implicating IL-5 as a 
potentially-important cytokine for regulatory B cell function. Data presented herein confirmed 
this finding, demonstrating that IL-5 can indeed expand a population of B cells that are 
enriched for FasL+ B cells and capable of IL-10 secretion. B cells stimulated with IL-5 displayed 
potent killing activity against CD4+ T cells, inducing apoptosis in targets cells in a FasL-
dependent and antigen-specific manner. 
Finally, we performed experiments to explore the effects of cytokines frequently associated 
with IL-5 on regulatory B cell activity. Somewhat unexpectedly, the results of these 
experiments revealed a novel antagonistic relationship between the type-2 cytokines IL-4 and 
IL-5 in their effects on regulatory/killer B cells in vitro. Specifically, IL-4 dominantly inhibited 
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both the enhanced killing activity of B cells as well as the enhanced secretion of IL-10 mediated 
by IL-5.   
 
2.2 Methods 
Mice: All protocols involving animals were approved by the University of Michigan Committee 
on the Use and Care of Animals (UCUCA). Wild-type DBA/1LacJ mice were obtained from our 
breeding colony at the University of Michigan or purchased from Jackson Laboratories. The 
cII-TCR transgenic mice were generated on the DBA/1LacJ background and recognize an 
immunodominant epitope of type 2 collagen (cII259-272) when presented by the MHC class II I-Aq 
molecule expressed in DBA/1 mice [147]. The presence of the transgene was confirmed by 
polymerase chain reaction genotyping in all animals.  
Flow Cytometry: Fluorochrome-conjugated antibodies and isotype controls were obtained from 
BD Biosciences (anti-CD19-APC, anti-CD19-PECy7, anti-B220-PECy7, anti-CD93-FITC, anti-CD23-
FITC, anti-IgM-PECy7, anti-CD21-PE, anti-CD24-PE, anti-CD5-APC, anti-CD1d-FITC, anti-CD125-
PE, anti-FasL-PE, anti-FasL-Biotin) or Biolegend (anti-CD3-APC, anti-CD9-FITC). Cells were 
incubated with anti-CD16/CD32 Fc Block (BD Biosciences) prior to staining and analyzed on an 
Accuri C6 flow cytometer. In all analyses, propidium iodide was used to exclude dead cells and 
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doublets were excluded by gating based on forward scatter height and area channels. Data 
were analyzed using Cytobank web-based software [172] or FlowJo v7.6.5 (Tree Star, Inc.).  
Fluorescence-Activated Cell Sorting: Splenocytes from naïve mice were stained with anti-CD19-
APC and anti-FasL-PE (BD Biosciences). CD19+FasL- and CD19+FasL+ populations were then 
isolated using a FACSAria II (BD Biosciences).  
Identifying IL-10-producing B Cells:  FasL- and FasL+ B cell populations obtained by FACS were 
cultured for five hours with 50 ng/mL phorbol myristate acetate (PMA), 1 µg/mL ionomycin, 
and 5 µg/mL lipopolysaccharide (LPS) in the presence of monensin (GolgiStop, BD Biosciences). 
B cells were then fixed (4% paraformaldehyde) and permeabilized (0.5% Saponin, 0.2% BSA,   
0.1% sodium azide in phosphate buffered saline) prior to staining with anti-IL10-FITC or 
isotype control antibody (BD Biosciences). No cells staining positive for IL-10 were detected in 
cultures without stimulation or in B cells treated with monensin in the absence of 
PMA/ionomycin/LPS stimulation (data not shown).  
B cell Isolation and Culture: B lymphocytes were positively-selected from single-cell splenocyte 
suspensions using anti-CD19-coated magnetic beads (Miltenyi Biotec). Isolated B cell 
populations were routinely >95% pure. Mouse CD40L-transduced NIH-3T3 fibroblasts (a gift 
from Dr. Kevin McDonagh) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% calf serum, penicillin/streptomycin, and L-glutamine [173]. For B cell 
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stimulation cultures, CD19+ cells were added to a confluent layer of irradiated (30 Gy) CD40L-
expressing fibroblasts in 24- or 96-well flat-bottomed culture plates in the presence or absence 
of 50 ng/mL recombinant mouse IL-5 and/or IL-4 (Peprotech Inc.). All stimulations were 
performed in DMEM supplemented with 10% fetal calf serum, penicillin/streptomycin, L-
glutamine, 50 µg/mL transferrin, and 5 µg/mL insulin.  After 5 days in culture, supernatants 
and B cells were collected for further study. Viable cells were enumerated using trypan blue 
exclusion. 
Proliferation Assay:  B cells were cultured with irradiated CD40L-expressing fibroblasts in the 
presence or absence of IL-5. After 4 days, 3H-thymidine was added (5 µCi final concentration) 
and cells were harvested after 18 hours in culture. Radioactivity was assessed by a scintillation 
counter. Control wells containing CD40L-fibroblasts alone or B cells cultured on non-
transduced NIH-3T3 fibroblasts showed no detectable proliferation in response to IL-5 (data 
not shown).  
Immunoblotting: Cell lysates from equal numbers of freshly-isolated CD19+ cells and B cells 
stimulated for five days with CD40L-expressing fibroblasts and cytokines were separated by 
SDS-PAGE and transferred to a PVDF membrane. Membranes were blocked and incubated with 
polyclonal rabbit anti-FasL IgG (Millipore) or anti-β-Actin (Cell Signaling). Antibody binding 
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was detected with an anti-rabbit IgG-HRP secondary antibody (Cell Signaling) and ECL reagent 
(Thermo Scientific). 
Apoptosis Assay: Splenocytes were harvested from cII-TCR transgenic mice and stimulated with 
2 µg/mL Concanavalin A for three days. CD4+ T cells were then negatively selected by magnetic 
activated cell sorting (MACS) and cultured with freshly-isolated CD19+ B cells or B cells 
stimulated for 5 days on CD40L-expressing fibroblasts with or without IL-5. CD4+ T cell 
populations were >90% CD4+ after negative selection. Apoptosis assays were performed in RPMI 
supplemented with 10% fetal calf serum, penicillin/streptomycin, L-glutamine, HEPES, sodium 
pyruvate, and β-Mercaptoethanol. After 18 hours of co-culture (1:1 effector-to-target ratio), 
cells were collected and stained with anti-CD4-PE, Annexin V-FITC (BD Biosciences), and 
propidium iodide. Prior to co-culture with CD4+ T cells, some B cells were incubated with 10 
µg/mL anti-FasL blocking antibody (R&D Systems) or an isotype control antibody for one hour 
and washed. To assess FasL-mediated “fratricide” between CD4+ T cells, control wells with T 
cells alone contained these antibodies for the full duration of culture. Apoptosis was measured 
by flow cytometry as the frequency of Annexin V+ cells within the CD4+ gated population.   
Enzyme-linked Immunosorbent Assay (ELISA):  B cells were cultured on CD40L-expressing 
fibroblasts for five days in the presence or absence of IL-5. Equal concentrations(7.5 x 105 
cells/mL) of stimulated B cells and freshly-isolated CD19+ B cells were then cultured in 96-well 
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flat-bottomed plates with either no further stimulation, or with PMA (50 ng/mL) and 
ionomycin (1 µg/mL). Supernatants were collected after 24 hours, and IL-10 was quantified by 
ELISA following manufacturer’s protocols (R&D Systems).  
Statistics: The Student’s t test was used to compare experimental groups using GraphPad Prism 
5.0 software. Levels of significance are denoted throughout as follows: *p<0.05, **p<0.01, 




Frequency and surface phenotype of FasL+ B cells 
It is well-established that the Fas/FasL signaling axis is critical for the maintenance of self-
tolerance, as mice bearing natural mutations in genes coding for either of these molecules 
develop spontaneous systemic autoimmunity [134, 135]. Cells expressing FasL are therefore 
potentially important in maintaining immune homeostasis and ultimately self-tolerance. To 
determine the cellular composition of FasL+ splenocytes, we examined FasL+ and FasL- 
splenocytes in naïve DBA/1 mice by flow cytometry.  The majority of FasL-expressing 
spleoncytes (~60%) showed high surface expression of the B cell markers B220, CD19, and IgM 
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(Figures 2-1A and 2-1B). Most of the remaining FasL+ splenocytes were CD3+ T cells, although a 
few apparent non-lymphoid cells showed some expression of FasL as well. We found similar 
results upon examining splenocytes from naïve CBA, C57BL/6, and Balb/c mice housed under 
identical conditions in our mouse colony (data not shown). B cells, therefore, appear to be the 
predominant FasL-expressing splenocyte in naïve mice. 
The B cell population in peripheral organs is comprised of functionally and developmentally 
distinct subsets that can be identified in part by differential expression of surface markers. 
Among these subsets, IL-10-producing B cells have been reported to be enriched in both the 
CD5+CD1dhigh (B10 cells) and CD23+CD21high transitional 2-marginal zone precursor (T2-MZP) B 
cell subsets, although most IL-10-secreting B cells are distributed among other B cell subsets 
[130-132]. Previous work showed that FasL+ B cells were enriched among CD5+ B cells, but had 
not further characterized their surface phenotype [146]. We therefore compared surface 
expression of several surface markers in FasL+ and FasL- B cells to understand how FasL+ B cells 
relate to previously-identified B cell subsets. CD19+FasL+ B cells displayed a modest but 
statistically significant enhancement in surface expression of CD5, CD1d, IgM, and CD24 than 
CD19+FasL- B cells (Figure 2-2). Surface levels of CD9, CD93, CD21 and CD23 were similar in both 
FasL+ and FasL- B cells.   
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To determine if CD5+CD1dhigh B cells were more frequent among the FasL+ B cells, we stained 
FasL+ and FasL- B cells for surface expression of CD5 and CD1d. These experiments showed that 
CD5+CD1dhigh B cells were indeed more frequent among FasL+ B cells than FasL- B cells (Figures 
2-3A and 2-3B). Reciprocally, the CD5+CD1dhigh B cell subset had a nearly four-fold enrichment 
for FasL+ B cells (Figure 2-3C). Although FasL+ B cells were enriched among CD5+CD1dhigh subset 
cells, most FasL+ B cells were not within this subset, indicating that, much like IL-10-producing 
B cells, FasL+ B cells are not found exclusively in a single B cell subset. A similar experiment 
comparing expression of CD23 and CD21 failed to find evidence of an increase in the frequency 
of CD23+CD21high T2-MZP B cells among the constitutively FasL+ B cells relative to FasL- B cells 








Figure 2-1: The majority of FasL+ splenocytes are B cells.  
Splenocytes from naïve mice were stained for surface expression of FasL and the cellular 
composition of FasL- and FasL+ subsets was examined by flow cytometry. (A) Representative 
dot plots of splenocytes stained with a T cell marker (CD3) and three independent B cell 
markers (B220, CD19, and IgM). (B) The frequency (mean ± SEM) of cells staining positive for 
the markers presented in (A) among FasL+ splenocytes. Data are representative of more 





Figure 2-2: FasL+ B cells have higher expression of CD5, CD1d, IgM, and CD24 than FasL- B 
cells.  
Representative histograms showing relative surface expression of markers for B cell subsets 
in CD19+FasL- and CD19+FasL+ B cells. Grey histograms represent isotype control antibody 
staining. Bar graphs depict the average median fluorescence intensity for cells obtained 




Figure 2-3: FasL+ B cells are enriched in the CD5+CD1dhigh B cell subset.  
(A) FasL- and FasL+ B cells were stained for co-expression of CD5 and CD1d. (B) The frequency 
of CD5+CD1dhigh cells (mean ± SEM) among FasL- and FasL+ B cells in replicate animals was 
measured. (C) Reciprocally, the frequency of FasL+ cells among all B cells and CD5+CD1dhigh B 
cells was measured. Data are representative of four independent experiments using at least 





Figure 2-4: CD23+CD21high B cells are not enriched among FasL+ B cells.  
(A) FasL- and FasL+ B cells were stained for co-expression of CD23 and CD21. (B) The 
frequency of B cell populations as gated in (A) among FasL- and FasL+ B cells in replicate 
animals was measured. (mean ± SEM) 
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FasL+IL-10+ B cells are extremely rare in naïve mice 
As FasL+ B cells shared some phenotypic similarities with the B10 cells, we next sought to 
determine whether these were discrete or overlapping cell populations by co-staining for both 
immunosuppressive molecules. Although FasL+ B cells can be readily identified without further 
stimulation, IL-10-producing B cells cannot be identified directly without several hours of in 
vitro stimulation with PMA/ionomycin/LPS in the presence of a secretion-blocking compound 
such as monensin [174].  Using previously-published methods for detecting IL-10-producing B 
cells, we initially attempted to stain for both surface FasL and intracellular IL-10 in the same B 
cells [175]. Unfortunately, the culture and fixation protocols necessary to identify IL-10-
producing B cells all-but eliminated FasL staining (Figure 2-5). Whether this result is due to the 
loss of FasL expression in FasL+ B cells or their death in culture is still an open question. 
Regardless, a consequence of this phenomenon is that any experimental protocols requiring 
identification of FasL+ B cells must be completed within 2-4 hours of isolation.  
Taking an alternative approach, we sorted splenocytes into CD19+FasL- and CD19+FasL+ subsets 
by FACS immediately after isolation from the spleen. This allowed us to identify and isolate 
FasL+ B cells within two hours of isolation - before FasL+ B cells are no longer detectable among 
splenocytes. After sorting, FasL+ and FasL- B cells were cultured for 5 hours with 
PMA/ionomycin/LPS in the presence of monensin, and subsequently fixed and stained for 
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intracellular IL-10. We found that IL-10-producing B cells were present at similar frequencies 
among both FasL+ and FasL- B cells (Figures 2-6A and 2-6B). While the majority of FasL+ B cells 
do not produce detectable IL-10 under these conditions, ~4% of FasL+ B cells produced IL-10 
upon ex vivo stimulation, suggesting that a rare subset of FasL+ B cells can express both 
immunosuppressive molecules and therefore may be capable of using multiple means of 
immune suppression. The FasL+ B cells that do secrete IL-10, however, are extremely rare, 
making up <0.1% of all splenic B cells (~2% of B cells are FasL+, and ~4% of FasL+ B cells produce 







Figure 2-5: Staining protocols for identifying IL-10-expressing B cells by intracellular 
staining significantly reduce FasL staining.  
Short-term culture reduces FasL surface staining in B cells. Splenocytes from naïve mice 
were cultured for 6 hours with PMA (50 ng/mL), ionomycin (1 µg/mL) and LPS (5 µg/mL), 
stained with anti-CD19 and anti-FasL (or isotype control), then fixed and stained for 











Figure 2-6: IL-10-producing B cells are not enriched in the FasL+ subset.  
FasL- and FasL+ splenic B cells from naïve mice were sorted by FACS and stimulated with 
PMA, ionomycin, and LPS in the presence of monensin for five hours. (A) Following 
stimulation, FasL- and FasL+ B cells were fixed and stained for intracellular IL-10. (B) 




FasL+ B cells have higher expression of the IL-5 receptor 
The CD5+CD1dhigh B cell subset is enriched for both FasL+ and IL-10-producing B cells, two 
subsets of B cells with potential regulatory function. Knowledge of the factors responsible for 
the growth or function of regulatory B cells might help identify molecular pathways with 
therapeutic potential for further study. To identify such factors, we sorted splenic B cells from 
naïve DBA/1 mice into CD5+CD1dhigh and CD5-CD1dhigh subsets by FACS and subsequently used 
microarrays to compare global gene expression between these sorted populations. These data 
are available from the NCBI GEO depository (Accession number GSE46245).  Among the most 
differentially-expressed genes were those encoding two components of the IL-5 receptor: the 
alpha chain (Il5ra) and the beta chain (Csf2rb). Both genes were expressed at greater than three-
fold higher levels in CD5+CD1dhigh B cells (data not shown). We therefore assessed surface 
expression of the alpha chain of the IL-5R (CD125) on FasL+ and FasL- B cells by flow cytometry 
and observed that FasL+ B cells displayed higher CD125 expression than FasL- B cells (Figures 2-
7A and 2-7B). With a nearly two-fold difference in median fluorescence intensity, CD125 was 
the most differentially-expressed surface marker between FasL+ and FasL- B cells of all tested in 







Figure 2-7: FasL+ B cells express higher levels of the IL-5 receptor than FasL- B cells.  
(A) Histograms comparing surface expression of CD125 in CD19-, CD19+FasL- and CD19+FasL+ 
cells. (B) Quantification of median fluorescence intensity of CD125 expression in CD19+FasL- 
and CD19+FasL+ B cells in replicate animals (mean ± SEM). (C) Fold difference in surface 
expression for B cell markers between CD19+FasL+ and CD19+FasL- B cells (mean ± SEM). The 
data for FasL (black bar) were obtained using a second anti-FasL antibody conjugated to a 
different fluorochrome than that used to select CD19+FasL+ cells. Data are representative of 




IL-5 and CD40L stimulation expands B cells enriched for FasL expression 
As FasL+ B cells showed higher expression of the IL-5 receptor, we hypothesized that IL-5 might 
be important for the survival or growth of these cells and therefore set out to test the effects of 
IL-5 on B cells in vitro. B cell survival is generally low in vitro, however, and as a result several 
techniques have been developed to improve the viability and yield of B cells in culture. Most of 
these techniques involve stimulation of B cells, either with mitogenic stimuli such as LPS, or 
with co-stimulatory molecules such as CD40 ligand (CD40L). Interpretation of experiments 
performed using these stimuli must be careful to take their effects into consideration; on the 
other hand, however, experiments performed in their absence have caveats as well, as B cells 
cultured without stimulation have low viability and die quickly in culture. We chose to 
evaluate the effects of IL-5 and other cytokines on B cells stimulated with CD40L as this is a 
physiologically relevant stimulus that B cells are likely to encounter in vivo. To provide this 
stimulation, we adapted a technique used for the maintenance of human B cells for culture of 
murine B cells. As outlined in Figure 2-8A, CD19+ B cells from naïve mice were isolated and 
cultured with a monolayer of irradiated NIH-3T3 fibroblasts stably expressing a vector 
encoding murine CD40 ligand (CD40L Fb). Culturing CD19+ B cells on CD40L Fb allowed for 
maintenance of B cell cultures for up to 14 days and was dependent upon CD40L expression, as 
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control fibroblasts without the CD40L expression vector did not increase B cell survival above 
that of B cells cultured in medium alone (data not shown). 
Using this culture system, we investigated the effects of adding recombinant murine IL-5 to 
cultures of CD19+ B cells. As seen in Figure 2-8B, the addition of IL-5 to CD19+ B cells cultured 
with CD40L Fb led to a dose-dependent increase in the number of B cells recovered after five 
days. At high concentrations of IL-5 (100 ng/mL), more B cells were collected after five days in 
culture than had been added, demonstrating that IL-5-induced proliferation of B cells. We 
confirmed increased proliferation in B cells treated with IL-5 by assessing 3H-thymidine 
incorporation after 5 days in culture (Figure 2-8C). Therefore, IL-5 promotes the growth and 
proliferation of B cells stimulated with CD40L. 
Next, we compared B cells cultured with IL-5 and CD40L to freshly-isolated CD19+ B cells for 
surface expression of FasL and markers associated with FasL+ B cells in vivo. B cells stimulated 
with IL-5 and CD40L showed higher surface expression of FasL, CD5, and CD1d (Figure 2-9A and 
2-9B), and were significantly enriched for FasL+ B cells (Figure 2-9C). Immunoblotting for FasL 
confirmed this result, as IL-5-stimulated B cells had readily-detectable FasL protein whereas 
FasL was not detectable in an equivalent number of freshly-isolated CD19+ B cells (Figure 2-9D). 
Interestingly, the small residual population of living B cells remaining after five days of culture 
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with CD40L Fb in the absence of IL-5 also displayed increased surface expression of FasL, CD5, 
and CD1d relative to freshly-isolated B cells (Figure 2-9B). 
Finally, we sought to assess the independent effects of CD40L and IL-5 on FasL expression in B 
cells. As primary CD19+ B cells survive poorly in the absence of CD40L stimulation, we instead 
used a mouse B cell-derived hybridoma cell line that grows independently of CD40 stimulation. 
By immunoblot, we found that IL-5 alone led to an increase in FasL expression, as did the co-
culture of B cells with CD40L Fbs (Figure 2-10). Stimulation with both CD40L and IL-5 led to a 
cooperative effect, as indicated by increased FasL protein relative to either stimulation 
condition individually (Figure 5F). From these data, we conclude that IL-5 is a growth factor for 










Figure 2-8: IL-5 and CD40L stimulation induce B cell proliferation.  
(A) Diagram of B cell co-culture experiments with CD40L-expressing fibroblasts for study of 
the effects of IL-5 on B cell growth and function. (B) CD19+ B cells were cultured as 
illustrated in (A) and harvested after five days. Viable B cells recovered from culture were 
quantified from replicate samples using a hemocytometer and trypan blue exclusion. The 
dotted line represents the concentration of B cells at the beginning of the experiment. (C) 
Proliferation of B cells cultured with CD40L-expressing fibroblasts in the presence or 





Figure 2-9: B cells stimulated with IL-5 and CD40L express higher levels of FasL, CD5, and 
CD1d. 
(A) B cells stimulated with CD40L in the presence or absence of IL-5 were stained for FasL, 
CD5, and CD1d and compared with freshly-isolated CD19+ B cells and B cells. (B) Median 
fluorescence intensity of surface markers stained as in (A) on freshly-isolated CD19+ B cells, 
B cells stimulated with CD40L, and B cells stimulated with CD40L and IL-5. (C) The frequency 
of FasL+ B cells among freshly-isolated CD19+ B cells and B cells stimulated with CD40L and 
IL-5 was measured by flow cytometry as in (D). (D) Cell lysates from equal numbers of 
freshly-isolated CD19+ B cells and IL-5-stimulated B cells were probed by immunoblot for 






Figure 2-10: CD40L and IL-5 have additive effects on FasL levels in a B cell-derived cell line.  
The murine B cell-derived hybridoma cell line CIIC1 was cultured for two days with CD40L-
expressing fibroblasts, IL-5 (50 ng/mL), or both CD40L-expressing fibroblasts and IL-5. Cell 
lysates from each condition were then probed for FasL and β-Actin proteins by immunoblot 
as in Figure 5G of the main text. The CIIC1 hybridoma was generated by fusing the Ag8.653 
myeloma cell line with a B cell from a DBA/1 mouse immunized with chick type 2 collagen 
emulsified in completes Freund’s adjuvant. 
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B cells stimulated with IL-5 and CD40L induce antigen-specific apoptosis in CD4+ T cells  
Although several types of cells are susceptible to FasL-mediated killing, this mechanism is 
especially important in preventing pathologic proliferation and activation of T cells. We 
therefore chose CD4+ T cells to serve as target cells in experiments testing the killing activity of 
stimulated B cells. While naïve CD4+ T cells are relatively protected from FasL-mediated killing, 
these same cells readily undergo apoptosis in response to Fas signaling after activation. To 
obtain activated, FasL-susceptible CD4+ T cells, splenocytes from cII-TCR transgenic (cII-TCR 
Tg) mice were cultured with Concanavalin A. After three days, CD4+ T cells were negatively-
selected from splenocyte cultures by MACS. T cells from these mice are heavily-enriched for 
transgenic expression of a MHC class II-restricted TCR specific for an immunodominant 
peptide of type-II collagen. APCs from MHCII-matched mice are able to present this peptide, 
and therefore the addition of this peptide to culture results in antigen-specific interactions 
between cII-TCR Tg T cells and APCs. 
Activated CD4+ T cells were co-cultured overnight (~18 hours) at a 1:1 ratio with B cells, and 
apoptosis in T cells was assessed by Annexin-V/propidium iodide staining. In the absence of 
cognate peptide, B cells stimulated with CD40L alone or in conjunction with IL-5 induced 
slightly higher levels of apoptosis than were induced by fresh CD19+ B cells (Figures 2-11A and 
2-11B). In the presence of cognate peptide, however, IL-5-stimulated B cells induced 
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significantly higher levels of apoptosis in CD4+ T cells than either freshly-isolated CD19+ B cells 
or B cells stimulated with CD40L alone (Figures 2-11A and 2-11B). Therefore, B cells stimulated 
with IL-5 and CD40L display potent antigen-specific killing activity. B cells stimulated with 
CD40L alone also induced antigen-specific apoptosis in T cells, but had significantly weaker 
killing activity relative to that of B cells stimulated with IL-5 and CD40L (Figures 2-11A and 2-
11B). 
To test the role of B cell-derived FasL in this killing activity, we pre-treated B cells for one hour 
with an anti-FasL blocking antibody or isotype control antibody prior to co-culture with CD4+ T 
cells. Blocking FasL on B cells significantly inhibited the antigen-specific killing function of 
CD40L–stimulated and IL-5/CD40L-stimulated B cells (Figures 2-11A and 2-11B). As activated 
CD4+ T cells can express FasL, it is important to evaluate the extent of FasL-mediated 
“fratricide” between CD4+ T cells in these experiments. The level of apoptosis in T cells 
cultured in the absence of B cells was not above baseline, and the presence of anti-FasL 
antibody for the duration of the experiment did not reduce apoptosis (Figures 2-11A and 2-
11B). 
Taken together, these results demonstrate that B cells stimulated with CD40L can induce 
antigen-specific and FasL-dependent cell death in cognate T cells, and that IL-5 strongly 




Figure 2-11: B cells stimulated with IL-5 and CD40L induce antigen-specific apoptosis in CD4+ 
T cells.  
Splenocytes were isolated from naive cII-TCR transgenic mice and stimulated in vitro with 
Concanavalin A. After three days in culture, CD4+ T cells were negatively-selected by MACS 
and co-cultured with freshly-isolated CD19+ splenic B cells or stimulated B cells at a 1:1 ratio.  





(legend continued from last page) 
Figure 2-11: B cells stimulated with IL-5 and CD40L induce antigen-specific apoptosis in CD4+ 
T cells.  
 
B cells were incubated with anti-FasL blocking antibody or an isotype control antibody for 1 
hour and washed with PBS prior to co-culture with CD4+ T cells. In wells with no B cells, 
anti-FasL antibody or isotype control antibody were directly added to culture wells to assess 
FasL-mediated “fratricide” between CD4+ T cells. Apoptosis was measured at 18 hours by 
flow cytometry as the percentage of CD4+cells that were positive for Annexin V staining. (A) 
Representative plots of gated CD4+ T cells for Annexin V and propidium iodide following co-
culture with B cells. (B) Quantification (mean ± SEM) from a single experiment as described 





IL-5 enhances secretion of IL-10 in CD40L-stimulated B cells 
Our initial microarray results demonstrated that expression of the IL-5 receptor was higher in 
CD5+CD1dhigh B cells, a population which is enriched for both FasL+ B cells and IL-10-producing B 
cells. As IL-5 enhanced FasL-mediated killing by B cells, we therefore hypothesized it might 
also enhance IL-10 secretion. Using the same system outlined in Figure 2-8A, we cultured B 
cells with CD40L Fb in the presence or absence of IL-5 for five days. B cells were then 
harvested, washed, and re-cultured at equal concentrations along with freshly-isolated CD19+ B 
cells. After 24 hours, culture supernatants were collected and IL-10 secretion was measured by 
ELISA. As seen in Figure 2-12A, only B cells stimulated with IL-5 and CD40L produced 
detectable amounts of IL-10, whereas IL-10 secretion was not detectable under these 
conditions from B cells stimulated by CD40L alone or from freshly-isolated B cells. In response 
to stimulation with PMA and ionomycin, B cells stimulated with CD40L alone secreted IL-10, 
and this secretion was greatly enhanced by the addition of IL-5 (Figure 2-12B). IL-5 therefore 






Figure 2-12: IL-5 enhances secretion of IL-10 in CD40L-stimulated B cells.  
CD19+ B cells were isolated by MACS from naïve mice and cultured for five days with CD40L-
expressing fibroblasts in the presence or absence of IL-5. B cells were then harvested, 
washed in PBS, and cultured overnight at equivalent cell concentrations in the presence or 
absence of stimulation with PMA and ionomycin. IL-10 in the culture supernatants was 
measured by ELISA. (A) IL-10 secretion from B cells after overnight culture with no further 
stimulation. (B) IL-10 secretion from B cells after overnight culture with PMA and 




IL-5-mediated induction of killer B cell function, but not FasL expression, is inhibited by IL-4 
IL-5 is most closely-associated with type-2 immunity, a stereotyped immune response that 
coordinates the action of many cell types in response to large multicellular pathogens such as 
parasitic worms. Previous work had shown that FasL+ B cells were more frequent in mice 
infected with the parasitic worm S. mansoni and those with chronic asthma, two conditions 
characterized by high levels of type-2 cytokines. We therefore hypothesized that IL-4, the 
hallmark cytokine of the type-2 response, might have an enhancing effect on the IL-5-
mediated killer B cell program.  
To test this, we assessed the apoptosis-inducing capacity of B cells cultured with CD40L Fb and 
IL-4, IL-5, or both cytokines simultaneously as in Figure 2-8A. B cells stimulated with IL-4 and 
CD40L did not display any detectable killing activity, in contrast to the measurable antigen-
specific apoptosis induced by CD40L stimulation alone and the robust killing displayed by B 
cells stimulated with IL-5 and CD40L Fb. (Figure 2-13A). When both IL-4 and IL-5 were present 
in B cell cultures, the resulting cells again displayed no detectable killing activity (Figure 2-
13A).  These data therefore suggest that, rather than enhancing the effects of IL-5, IL-4 instead 
strongly inhibited the killing function induced by IL-5 in B cells.  
The simplest mechanistic explanation for this inhibition of killing activity would be a 
reduction in FasL expression in B cells stimulated with IL-4. Somewhat unexpectedly, we 
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instead found essentially equivalent amounts of FasL protein (on a per cell basis) in all B cells 
stimulated with CD40L, regardless of the addition of cytokines (Figure 2-13B). Therefore, IL-4 







Figure 2-13: IL-5-mediated induction of killer B cell function, but not FasL expression, is 
inhibited by IL-4.  
CD19+ B cells from naïve mice were cultured for five days with IL-4, IL-5, or both cytokines 
concurrently. (A) The ability of B cells stimulated under these conditions to induce 
apoptosis in activated CD4+ T cells was then assessed as in Figure 6. Apoptotic cells were 
identified and enumerated (mean ± SEM) on the basis of positive staining for Annexin V by 
flow cytometry. (B) B cells were cultured with CD40L-expressing fibroblasts in the presence 
or absence of IL-4 and IL-5, or in the presence of both cytokines. Cells were harvested after 5 
days in culture and cell lysates were probed for FasL and B-Actin proteins as in Figure 5G. 




IL-4 dominantly inhibits IL-5-mediated enhancement of IL-10 secretion B cells  
The ability of IL-4 to inhibit IL-5-induced killer B cell activity prompted us to assess its effect 
on IL-5-induced IL-10 secretion. To this end, B cells were cultured with CD40L Fb and 
increasing concentrations of IL-5 in the presence or absence of IL-4. B cells were harvested 
after five days in culture, washed, counted, and re-cultured at equivalent cell concentrations. 
After 18 hours, culture supernatants were collected and IL-10 concentration was assessed by 
ELISA as in Figure 2-11. As we saw previously, the addition of IL-5 to B cells stimulated with 
CD40L enhanced secretion of IL-10 (Figure 2-14). In the presence of IL-4, however, no 
enhancement of IL-10 secretion was mediated by IL-5 (Figure 2-14). This inhibition appears 
quite robust, as low concentrations of IL-4 (10 ng/mL) were able to inhibit the effects of high 






Figure 2-14: IL-4 dominantly inhibits IL-5-mediated enhancement of IL-10 secretion B cells.  
CD19+ B cells were isolated by MACS from naïve mice and cultured for five days with CD40L-
expressing fibroblasts with increasing concentrations of IL-5 in the presence or absence of 
10 ng/mL IL-4. B cells were then harvested, washed in PBS, and cultured overnight at 
equivalent cell concentrations. IL-10 in the culture supernatants was measured by ELISA. 
Data are representative of more than 5 individual experiments.  
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2.4 Discussion  
The Surface Phentoype of FasL+ B Cells 
The Fas/FasL signaling axis is essential for maintaining self-tolerance, and therefore cells 
expressing high levels of FasL are likely to be critical for this function. Among splenocytes in 
naïve mice, B cells are the predominant FasL+ cell population. FasL+ APCs have demonstrated 
efficacy in establishing tolerance upon adoptive transfer, as both endogenous unaltered B cells 
and APCs engineered to express FasL can induce antigen-specific tolerance [151, 176, 177]. In 
light of these studies, further examination of endogenous FasL+ APCs is warranted to 
understand their importance in maintaining immune homeostasis and self-tolerance.  
The surface phenotype of FasL+ B cells bears some similarity to that reported for the B10 subset 
of IL-10-producing B cells [131]. Specifically, FasL+ B cells are moderately enriched in the 
CD5+CD1dhigh B cell subset, but only a minority of FasL+ B cells is found within this B cell subset. 
IL-10-producing B cells are also enriched among CD5+CD1dhigh B cells, but only ~25% of IL-10-
producing B cells reside in the CD5+CD1dhigh subset [131, 132]. Despite their shared enrichment 
in the CD5+CD1dhigh B cell subset, IL-10-producing cells are not more frequent among FasL+ B 
cells than FasL- B cells. The ~4% of FasL+ B cells that do secrete IL-10, however, might represent 
a multi-potent population of killer/regulatory B cells. In naïve mice, these multi-potent 
suppressor B cells are extremely rare, making up <0.1% of all splenic B cells (~2% of B cells are 
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FasL+, and ~4% of FasL+ B cells produce IL-10 after ex vivo stimulation). Although FasL+IL-10+ B 
cells might be more frequent in animals mounting an active immune response, their extreme 
paucity in naïve mice has made further characterizing these cells technically difficult. 
FasL+ B cells also share some phenotypic characteristics with B-1a cells (CD5+IgMhigh) and MZ B 
cells (CD1dhigh). These innate-like B cell subsets share functional similarities [22, 37], and arise 
from a common precursor population distinct from that of follicular B-2 cells [20, 178]. As 
discussed earlier, innate-like B cells are the main source of natural anti-inflammatory IgM 
antibodies that help maintain immune homeostasis in a variety of ways [113, 115, 179]. 
Currently, only circumstantial evidence supports a link between regulatory B cells and innate-
like B cells, and more study is required to determine the relationship between these cell types.  
IL-5 is a Growth Factor for Regulatory B Cells 
Increasing the frequency or activity of regulatory immune cell populations is an as-yet 
unrealized potential therapeutic strategy for combating inflammatory conditions such as 
autoimmune diseases. The initial knowledge required to develop a therapy using such a 
strategy is a thorough understanding of the factors important for the growth or function of a 
given regulatory cell population. The work presented in this chapter demonstrates that B cells 
stimulated with IL-5 secrete the anti-inflammatory cytokine IL-10 and can induce FasL-
mediated apoptosis in CD4+ T cells. This finding is consistent with previous studies 
[75] 
 
demonstrating that FasL+ B cells were increased in mice infected with S. mansoni and in a mouse 
model of chronic allergen-induced asthma, two conditions characterized by an increase in T 
cell activation and production of IL-5 and other type 2 cytokines [146, 180]. 
It is important to note that the effects of IL-5 on the immune system are pleiotropic, as both 
pro- and anti-inflammatory effects have been reported. IL-5 has a role in generating optimal 
antibody responses, as mice in which B cells are unable to respond to IL-5 signaling are 
defective in antibody-secreting plasma cell differentiation and have reduced levels of 
circulating antibodies [181]. Accordingly, over-expression of IL-5 results in increased antibody 
levels and hypereosinophilia, and mice deficient in IL-5 receptor signaling have reduced levels 
of antibodies [156, 182]. In contrast, IL-5 is a critical survival factor for peritoneal B-1 cells, and 
administration of IL-5 leads to an increase in secretion of anti-inflammatory natural antibodies 
by B-1 cells [117, 183]. In a rat model of multiple sclerosis, IL-5 administration had therapeutic 
effects, acting at least in part by inducing FoxP3+ regulatory T cells [184]. Further work is 
needed in examining the role of IL-5 in autoimmunity, however, as mice deficient in IL-5 
appeared to have a similar clinical course of EAE [185]. None-the-less, because of its ability to 
induce at least three mechanisms of immune suppression in B cells, the IL-5/IL-5 receptor axis 




Although the in vivo target(s) of FasL+ B cells remains to be determined, we show here that IL-5 
stimulated FasL+ B cells induce apoptosis in activated CD4+ T cells. This killing function was 
greatly increased upon the addition of antigen, suggesting that FasL+ B cells preferentially 
target T cells based upon antigen specificity. The potency of this killing effect is especially 
noteworthy, as an effector-to-target ratio 10-20 fold lower than usually required to measure 
cytotoxic activity resulted in significant levels of apoptosis in CD4+ T cells. Negative selection is 
thought to eliminate T cells which respond to self-antigens, however some autoreactive T cells 
are none-the-less present among peripheral T cells [186]. As innate-like B cells frequently 
possess self-reactive BCRs, the antigens presented by FasL+ B cells would be expected to be 
enriched for self-antigens due to BCR-mediated endocytosis and processing of host-derived 
molecules [22]. FasL+ B cells may therefore play a role in maintaining self-tolerance by 
eliminating CD4+ T cells recognizing self-antigens that escape negative selection in the thymus. 
While it has been reported that mice with a targeted deletion of the Fasl gene in B cells show 
symptoms of autoimmunity, further work is needed to evaluate the importance of this 
mechanism in animal models of autoimmunity [148]. 
IL-4 Dominantly Inhibits IL-5-induced Regulatory Mechanisms in B Cells 
While B cells treated with IL-5 were enriched for B cells with regulatory functions, this 
enrichment was completely blocked by the addition of IL-4. Intriguingly, despite the vast 
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difference in their killing activity there is no consistent difference in FasL protein levels (on a 
per cell basis) between B cells stimulated with IL-5 and CD40L and those stimulated with IL-4, 
IL-5, and CD40L (Figure 2-12B). Thus, IL-4 must inhibit the FasL-mediated killing function 
induced by IL-5 through other mechanisms. These data are in agreement with previous 
findings regarding induction of FasL+ B cells by IL-4 and IL-10 in the schistosome granuloma 
model [146]. While perhaps unexpected, this result is consistent with what is known regarding 
the complex and unusual regulation of FasL. Killer cells such as cytotoxic T cells and NK cells 
keep most FasL protein sequestered in the secretory lysosome, an endosomal-like intracellular 
compartment [28, 156]. FasL is then moved to the cell surface in response to signals received 
upon encounter with an appropriate target cell. There are several nodes of regulation in this 
process upon which IL-4 may act, such as preventing the phosphorylation events required for 
the transport of FasL to the secretory lysosome, inhibiting the movement of the secretory 
lysosome to the cell surface, or reducing the signals received from target cells that result in 
mobilization of secretory lysosome granules to the cell surface [165]. This result also suggests a 
prominent role for CD40 signaling in FasL induction in B cells, as even the small population of 
B cells that survived with only CD40L stimulation expressed FasL and had measurable FasL-
mediated killer function. Similar effects of CD40 ligation on FasL expression have been noted in 
mouse Langerhans cells, human hepatocytes and ovarian cancer cells [187-189]. Additionally, 
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CD40 signaling results in down-regulation of BCL6, a transcription factor that competes with 
STAT3 for DNA binding sites [187, 188]. CD40 signaling therefore enhances STAT3 binding and 
facilitates the downstream effects of cytokines that signal through STAT3 by reducing levels of 
BCL6. The IL-5 receptor has been shown to activate STAT5, a transcription factor which shares 
many binding sites with STAT3 throughout the genome [165]. Therefore, it is possible that 
CD40 signaling acts in synergy with IL-5-receptor signaling to induce a regulatory phenotype 
in B cells. Using a B cell-derived cell line, we found that both CD40L and IL-5 stimulation 
individually induced FasL expression in an additive manner, suggesting that these two 
pathways might work in concert to increase FasL expression in B cells (Figure 2-13). 
It has been suggested that, rather than existing as a homogenous population, regulatory B cells 
can arise from both B-1 and B-2 cells [190]. In this case, it is likely that different growth factors 
would differentially act on regulatory B cells from these different lineages. Recently the 
cytokine IL-21 was identified as a growth factor for IL-10-producing B cells using a similar 
culture system as we have used in this study [191]. As IL-21 is associated with the growth of 
follicular B cells, it is possible that IL-21 drives the growth of B-2-derived regulatory B cells, 
while IL-5 induces the growth of B-1-derived regulatory B cells. Given their differing niches, 
regulatory B cells derived from B-2 cells might be more effective in inhibiting autoimmunity in 
the peripheral lymphoid organs, whereas B-1-derived regulatory cells might be more effective 
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at mucosal sites. More work is required, however, to clarify the differences and similarities of 
regulatory B cells stimulated by IL-21 or IL-5, as these two types of regulatory B cell might also 
target different cells in vivo.  
As B cells stimulated with IL-5 and CD40L secrete IL-10 and are potent inducers of apoptosis in 
activated T cells, we have made several attempts to assess their immunosuppressive function 
in vivo by adoptive transfer in a collagen-induced arthritis model. Our results thus far have 
failed to clearly define an effect for these transferred cells, as mice receiving untreated B cells 
or PBS have a similar disease course as those receiving IL-5-stimulated B cells (data not 
shown). B cells stimulated with IL-5 and CD40L, although enriched for B cells with regulatory 
function, still display heterogeneity. Given the reported pleiotropic effects of IL-5 on B cells 
outlined above, it is possible that IL-5 and CD40L stimulation results in expansion of a 
population of cells that is enriched for regulatory B cells but not exclusively 
immunosuppressive in nature. Recently-published data reporting the strong effects of IL-21 on 
regulatory B cell growth showed a similar outcome, as in vitro treatment of CD19+ B cells with 
IL-21 led to enrichment of IL-10-producing B cells, but IL-10-producing B cells still comprised 
only a minority of B cells in culture [191]. In vivo suppression of autoimmunity was only 
demonstrated by IL-21-stimulated B cells that had been sorted from a heterogeneous 
population after culture. It is also possible that, as mentioned above, B-1-derived regulatory B 
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cells exert their immunosuppressive effects at locations distinct from those of B-2-derived 
regulatory B cells, and therefore the function of these cells would be better assessed in a 
different model system. Further work is therefore warranted to definitively demonstrate a role 
for IL-5 in the generation of immunosuppressive B cells in vivo, and this is an important caveat 
to this study. 
In summary, the data presented herein characterize the phenotype of FasL+ B cells and 
demonstrate that FasL+ B cells are enriched in the CD5+CD1dhigh B cells subset. A portion of FasL+ 
B cells are multi-potent as they express IL-10 in addition to FasL, but these FasL+IL-10+ B cells 
are extremely rare in naïve mice, representing <0.1% of all splenic B cells. Additionally, we 
show here for the first time that IL-5 is an inducer or enhancer of at least two 
immunosuppressive mechanisms in regulatory B cells, as treating splenic B cells with IL-5 and 
CD40L expanded a population of B cells with potent FasL-mediated T cell-killing activity, and 
IL-5 enhanced IL-10 secretion from CD40L-stimulated B cells. Finally, IL-4 strongly inhibited 
the B cell killing activity mediated by IL-5, suggesting that cross-talk between these type-2 
cytokines might be important  in modulating the activity of regulatory B cells (Figure 2-15). 
Understanding the specifics of this IL-4/IL-5 axis in regards to regulatory B cells could provide 
new targets for the design of therapeutic strategies for patients with autoimmune disorders or 









Figure 2-15: IL-4 and IL-5 have antagonistic effects on regulatory B cell function.  
B cells stimulated with IL-5 are enriched for FasL+ B cells, have enhanced antigen-specific T 
cell killing activity, and secrete IL-10. In the presence of IL-4, these effects of IL-5 are 
completely eliminated.  
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2.5 Future Directions 
What signaling pathways downstream of IL-5 are important for inducing regulatory B cell function? 
The identification of IL-5 as a novel inducer of regulatory B cell function provides a new 
signaling axis to target with therapeutics. IL-5 binding to its receptor initiates activation of 
several signaling pathways (Figure 2-16). The Janus kinases (JAK) JAK1 and JAK2 associate with 
the receptor complex, and in turn activate the signal transducer and activator of transcription 
(STAT) molecules STAT1 and STAT5. Colonel Bruton’s tyrosine kinase (Btk), a molecule 
important in the function of most B cells, is also activated by IL-5-receptor signaling. 
Compounds that inhibit the function of either JAKs or Btk are currently available, some of 
which are the subject of ongoing clinical trials. Using these compounds, it is possible to assess 
the respective importance of JAKs and Btk in mediating the effects of IL-5 on B cells in vitro.  
Treating animals with these compounds is feasible as well, although it is difficult to 
definitively demonstrate the mechanism of action in these experiments as JAKs and Btk are 





Figure 2-16: Summary of signaling molecules downstream of the IL-5-receptor.  
The IL-5 receptor activates multiple signaling pathways, including a JAK-STAT pathway 
consisting of JAK1 and JAK2 signaling through STAT1/STAT5. Additionally, signaling 
through PI3K leads to the activation of Btk in response to IL-5 receptor signaling.  
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How does IL-4 inhibit the effects of IL-5? 
The IL-5-mediated enhancement of regulatory B cell function was dominantly inhibited by IL-
4, suggesting that cross-talk between these type-2 cytokines is important in modulating the 
activity of regulatory B cells. How IL-4 mediates this inhibition remains unknown. We found 
that levels of FasL in B cells treated with IL-5 alone were essentially equal on a per cell basis 
with those treated with both IL-5 and IL-4, despite the drastic difference in the killing activity 
between these cells. This suggests that IL-4 interrupts the actions of IL-5 through a mechanism 
unrelated to the production of FasL protein. 
As mentioned above, post-transcriptional regulation is important for the proper trafficking of 
FasL protein. IL-4 can affect this proper trafficking at several nodes in the regulatory circuit. 
First IL-4 might inhibit the movement of FasL to the secretory lysosome, and therefore FasL is 
improperly sorted or degraded. To investigate this possibility, fluorescent microscopy can be 
used to determine the intracellular location of FasL in B cells treated with IL-5 alone or in 
conjunction with IL-4. This can be done by staining with fluorescently-labeled antibodies to 
FasL and markers specific for subcellular compartments (such as CD63 for the secretory 
lysosome), or making expression vectors for FasL fusion proteins with fluorescent labels. Once 
FasL reaches the cell surface, it is cleaved and inactivated by metalloproteases, and it is also 
possible that IL-4 up-regulates the activity of FasL-cleaving proteases. Therefore if IL-4 acts 
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through this mechanism, B cells stimulated with IL-4 should display better killing function in 
the presence of protease inhibitors. In T cells and NK cells, signals from the target cell initiate 
the movement of FasL from the secretory lysosome to the cell surface. While it is still unknown 
if a similar mechanism exists in B cells, the antigen-specificity of B cell-mediated killing 
suggest that interaction with the target cell can enhance killing. Therefore IL-4 could 
potentially inhibit the killing efficiency of B cells by inhibiting the signal received by the B cell 
to initiate FasL mobilization.  
The relevance of this IL-4/IL-5 antagonism in vivo remains to be investigated as well. While 
expression of IL-4 and IL-5 is coordinately regulated in Th2 cells, other cell types secrete IL-5 
and little or no IL-4. Among these cells are recently-identified innate lymphoid cells [192-194]. 
These cells are the major producers of IL-5 under homeostatic conditions, and while present 
but infrequent in the spleen, they are heavily enriched in locations where immunoregulation 
is essential for maintaining tolerance to innocuous environmental antigens and commensal 
microbes, such as lymphoid structures associated with the lung and intestine. One role for 
these innate IL-5-producing lymphoid cells might therefore be to help preserve immune 
homeostasis at these sites through IL-5-mediated induction of regulatory B cell functions. It 
has also been reported that as murine Th2 cells are activated over time they transition from 
producing both IL-4 and IL-5 to producing exclusively IL-5 [195]. This is consistent with our 
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previous finding that mice chronically infected with S. mansoni have increased numbers of 
FasL+ B cells [145], and suggests a model in which the return to homeostasis at the cessation of 
type 2 responses includes IL-5-mediated induction of regulatory B cells.  
Are B cells stimulated with IL-5 heterogeneous?  
It still remains to be demonstrated that B cells stimulated with IL-5 are indeed regulatory in 
vivo, as our experiments in the collagen-induced arthritis model were inconclusive. The 
outcomes of adoptive transfer experiments can be affected by many variables, and this is true 
for even well-established regulatory populations such as natural regulatory T cells (nTregs). 
While nTregs can prevent collagen-induced arthritis (CIA) in DBA/1 mice, they fail to do so in 
another model of adjuvant-induced arthritis in BALB/c mice [2,3]. Additionally, adoptive 
transfer of nTregs can prevent CIA if transferred before disease onset, but no suppression is 
observed if the transfer occurs after disease has been established [4]. Therefore, although 
adoptive transfer experiments are sometimes capable of establishing the regulatory function 
of a cell population, a negative result in a single disease model does not preclude a suppressive 
function.  
The apparent lack immunosuppressive function in vivo may be in part the result of 
heterogeneity among IL-5-stimulated B cells. As outlined above, there is good evidence that IL-
5 has both pro- and anti-inflammatory effects on B cells, and therefore stimulation with IL-5 is 
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likely to result in a population of cells that, while enriched for regulatory B cells, are not 
exclusively immunosuppressive in nature. Recently-published data from the Tedder lab 
reporting the strong effects of IL-21 on regulatory B cell growth showed a similar outcome, as 
in vitro treatment of CD19+ B cells with IL-21 led to enrichment of IL-10-producing B cells, but 
IL-10-producing B cells still comprised only a minority of B cells in culture [191]. In vivo 
suppression by B cells was only demonstrated in this study by sorting immunosuppressive B 
cells from the heterogeneous IL-21-stimulated B cell cultures. Whether immunosuppressive B 
cells can be identified among IL-5-stimulated cells by a difference in surface marker expression 








B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand  




To identify a cell line suitable for the study of FasL in B cells, we screened a panel of B cell-
derived cell lines for FasL expression, including more than 20 independent lymphoblastoid cell 
lines (LCLs). Unexpectedly, we found that all LCLs tested for this study showed robust 
expression of FasL as determined by immunoblot. In contrast to endogenous murine FasL+ B 
cells, LCLs maintained nearly all of their FasL protein intracellularly, with little or no surface 
FasL detectable by flow cytometry. 
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As FasL can be secreted on exosomes by NK cells and CTLs, we then tested for the presence of 
FasL in LCL-derived exosomes. By immunoblot, we confirmed that both FasL and MHCII 
proteins were present in exosomes secreted by LCLs. Using a bead-based exosome capture 
assay, we used anti-MHCII-coated polystyrene beads to capture MHCII+ exosomes, and found 
evidence for the presence of FasL among MHCII+ exosomes by flow cytometry, indicating that 
LCLs can produce MHCII+FasL+ exosomes. 
To test the apoptosis-inducing ability of LCL-derived exosomes, we used two independent 
experimental approaches. First, we stimulated T cells with staphylococcal enterotoxin A (SEA) 
in the presence of exosomes, and assessed apoptosis among CD4+ T cells. In the presence of 
SEA, exosomes derived from an autologous LCL induced significant levels of apoptosis. 
Secondly, we stimulated PBMCs from another donor with an immunodominant peptide of 
tetanus toxoid (TT). After activation and enrichment for T cells reacting to TT peptide, we 
isolated CD4+ T cells and cultured them overnight with autologous LCLs in the presence or 
absence of TT peptide. As expected, we found that exosomes loaded with TT peptide were able 
to induce significant levels of apoptosis among activated CD4+CD62L- T cells, and this killing 
was partially blocked by the addition of an anti-FasL blocking antibody. 
Finally, we attempted to isolate B cell-derived exosomes from the spleens of mice. To do so, we 
used antibody-coated polystyrene beads to bind exosomes with B cell-specific markers and 
[90] 
 
stained them for FasL. We found that FasL was present on exosomes bound by anti-IgM-coated 
beads, suggesting that IgM+FasL+ exosomes are present in the mouse spleen. 
 
3.2 Methods 
Preparation of Peripheral Blood Mononuclear Cells:  All donors provided informed consent prior to 
their participation in this study. Blood was obtained by venipuncture and collected into 
syringes containing sodium heparin. Following a 1:1 dilution with un-supplemented RPMI 
1640, blood was gently layered onto Histopaque-1077 (Sigma Aldrich) in 50 mL centrifuge 
tubes. Buffy coats containing peripheral blood mononuclear cells were collected from tubes 
following centrifugation at 1,200 x g for 30 minutes at 20oC.  
Cell Lines: Lymphoblastoid cell lines were prepared according to established techniques for the 
transformation of B cells by Epstein-Barr virus [196]. Cell lines used were derived from either 
healthy donors and generated in our laboratory, or were from a collection of LCLs derived 
from monozygotic twin pairs discordant for rheumatoid arthritis (a kind gift from Dr. Joseph 
Holoshitz, University of Michigan). LCLs were maintained in RPMI 1640 media supplemented 
with 20% FBS, 2% L-glutamine, 1% penicillin/streptomycin, 1% non-essential amino acids, and 
1% sodium pyruvate. Most cell lines were kept in culture continuously for longer than 2 
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months with no detectable changes in growth, viability, or experimental results. Once or twice 
a week, LCL cultures were split 1:3, and kept in a 37oC 5% CO2 incubator. 
Immunoblotting: LCLs and LCL-derived exosomes were lysed in SDS buffer prior to separation by 
SDS-PAGE and transfer to a PVDF membrane. Membranes were blocked and incubated with 
polyclonal rabbit anti-FasL IgG (Cell Signaling), mouse anti-HLA-DR (Abcam, clone TAL 14.1) or 
polyclonal rabbit anti-β-Actin (Cell Signaling). Antibody binding was detected with an anti-
rabbit or anti-mouse IgG-HRP secondary antibody (Cell Signaling) and ECL reagent (Thermo 
Scientific). 
Flow Cytometry: PE-conjugated anti-FasL and isotype control antibody was obtained from 
Biolegend (clone NOK-1). LCLs were incubated with anti-CD16/CD32 Fc Block (BD Biosciences) 
prior to staining and analyzed on a Beckman Coulter FC500 flow cytometer. For intracellular 
staining, LCLs were fixed for 20 minutes at room temperature in 4% PFA, washed three times 
with PBS, and permeabilized with 0.5% saponin buffer prior to staining with anti-FasL. For 
apoptosis staining, Annexin-V-FITC (eBioscience) was used to identify cells in early apoptosis 
and propidium iodide was used to identify dead cells. Data were analyzed using Cytobank web-
based software [197] or FlowJo v7.6.5 (Tree Star, Inc.). 
Exosome Isolation and Preparation From LCL Culture Supernatants: Exosome-free FBS was produced 
by centrifuging FBS overnight at 100,000 x g to remove any bovine-derived exosomes. Culture 
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supernatants from LCL cultures were spun at 500 x g for 10 minutes to remove cells, followed 
by a spin at 10,000 x g for at least 1 hour to remove large cellular debris and microparticles. 
Exosomes were obtained by centrifugation at 100,000 x g for 1-4 hours. The resulting exosome 
pellets were diluted once with PBS prior to another 100,000 x g centrifugation, after which 
pellets were re-suspended in a small volume of PBS. Protein concentration was used as a proxy 
measure for the amount of exosomes in a given re-suspension, and was determined by BCA 
assay. In some cases, supernatant from bulk cultures of LCLs were concentrated using a 100 
kDa filter prior to exosome isolation by centrifugation. 
Density Gradient Centrifugation: Serial dilutions of iodixanol (OptiPrep; Sigma-Aldrich) were 
prepared with PBS, with densities ranging from 1.03 g/mL to 1.27 g/mL. One milliliter of each 
density fraction was added sequentially to an ultracentrifuge tube so as to maintain a 
discontinuous gradient. A sample of LCL-derived exosomes in solution was placed on top of the 
density gradient and centrifuged at 100,000 x g for 1 hour. Layers were then removed to 
separate tubes and diluted in PBS, and diluted fractions were centrifuged in individual tubes 
overnight at 100,000 x g. Pellets from each density fraction were lysed in an equal amount of 
SDS buffer, and interrogated for FasL and MHCII by immunoblot. 
Exosome Bead Capture Experiments: Polystyrene beads (~6.7 µm diameter) coated with 
streptavidin were obtained from Corpuscular or Spherotech. Beads were coated for 1 hour at 
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20oC with biotinylated antibodies against human HLA-DR (Biolegend, clone L243), mouse IgM 
(BD Biosciences, clone R6-60.2), mouse CD19 (BD Biosciences, clone 1D3), or appropriate 
isotype controls. After washing, antibody-coated beads were incubated for several hours with 
exosomes at 4oC with gentle agitation. Unbound exosomes were then washed away, and bead-
bound exosomes were stained for FasL and subsequently analyzed on a Beckman Coulter FC500 
flow cytometer. 
Exosome-induced Apoptosis Assays (SEA): CD4+ T cells were isolated from whole blood by 
RosetteSep Human CD4+ T cell Enrichment Cocktail (Stem Cell Technologies) and stimulated 
for 6 days with Staphylococcal enterotoxin A (10 ng/mL; Sigma-Aldrich) in the presence or 
absence of exosomes from an autologous LCL. T cells were then harvested and apoptosis was 
assessed by Annexin-V/propidium iodide staining among CD4+ T cells. 
Exosome-induced Apoptosis Assays (TT peptide): PBMCs were isolated from whole blood and 
stimulated for 12 days with an immunodominant peptide of tetanus toxoid (10 µg/mL). This 
donor had received a scheduled booster vaccination against tetanus within 2 months of these 
experiments. CD4+ T cells were separated from PBMC cultures by negative selection by MACS 
(Miltenyi Biotec) and cultured overnight with exosomes derived from an autologous LCL in the 
presence or absence of the stimulating peptide. The activity of FasL was blocked in culture by 
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the addition of anti-FasL antibody (Biolegend; clone NOK-1). Apoptosis was assessed in T cell by 
Annexin-V/propidium iodide staining among activated CD4+CD62L- T cells. 
Mice: All protocols involving animals were approved by the University of Michigan Committee 
on the Use and Care of Animals (UCUCA). Mice expressing the human MHCII gene, DR4-AE0 
transgenic mice (C57BL/6 background), were obtained from our breeding colony at the 
University of Michigan. The presence of the transgene was confirmed by polymerase chain 
reaction genotyping in all animals.  
 
3.3 Results 
A high frequency of LCLs constitutively produce intracellular FasL protein 
To study the regulation and trafficking of FasL in B cells, we obtained several B cell-derived cell 
lines to screen for FasL expression. Among the cell lines tested were several lymphoblastoid 
cells lines generated by transformation of human peripheral blood B cells with an attenuated 
form of the Epstein-Barr virus (EBV). By immunoblotting for FasL, we found that all LCLs 
tested (>20 independent lines) displayed robust and constitutive expression of FasL protein 
(Figure 3-1A). Expression of FasL in other types of B cell-derived cell lines such as human B cell 
lymphomas was sporadic (data not shown). We therefore conclude that a high frequency of 
[95] 
 
cell lines made by transformation of human B cells with EBV constitutively produce FasL 
protein. 
We next sought to determine the cellular localization of FasL in LCLs by flow cytometry. To 
this end we stained the surface of LCL cells with anti-FasL or an appropriate isotype control 
antibody. Somewhat surprisingly, we found little or no detectable FasL on the surface of all 
LCLs tested (Figure 3-1B). After fixation and permeabilization, however, we were able to detect 
intracellular FasL in all LCLs tested (Figure 3-1B). It therefore appears that while LCLs 







Figure 3-1: A high frequency of LCLs constitutively-produce intracellular FasL protein. 
(A) Equivalent numbers of LCLs and control cell lines were lysed and probed for expression 
of FasL protein by immunoblot. (B) LCLs were fixed and stained for surface FasL, or 
permeabilized with saponin buffer for intracellular FasL staining by flow cytometry. Results 
are representative of at least three LCLs tested. 
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LCLs secrete exosomes containing FasL and MHC class II 
Lymphoblastoid cell lines are known to spontaneously secrete exosomes, but there are no 
reports of LCL-derived exosomes containing FasL [167]. Additionally, the secretory lysosome is 
the default destination for FasL in cells which possess this compartment [155]. We therefore 
hypothesized that as LCLs express robust amounts of FasL, this FasL is likely to be sorted to the 
secretory lysosome and secreted on exosomes. To test this hypothesis, we collected 
supernatants from several independent LCLs and isolated exosomes from these supernatants 
using ultracentrifugation. Briefly, cells and large debris were removed from supernatants by 
centrifugation at 500 x g and 10,000 x g, respectively. To pellet exosomes, the cleared 
supernatants were spun between at 100,000 x g for 1-4 hours. The resulting exosome pellets 
were lysed with SDS buffer and probed for expression of FasL and HLA-DR by immunoblot. FasL 
was detectable in the exosome fraction from all LCLs tested (Figure 3-2A). We also confirmed 
that MHCII molecules were present in LCL-derived exosomes, as we found abundant HLA-DR in 
the exosome pellets as well (Figure 3-2A). 
The pellet obtained by centrifuging supernatants at 100,000 x g can potentially be 
contaminated with large soluble complexes or other types of cell debris. It has been reported 
that exosomes have a characteristic density distinct from other membrane fragments or 
microparticles [167]. We therefore spun re-suspended LCL-derived exosomes through a 
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discontinuous density gradient made by serial dilution of iodixanol in PBS. After spinning for 1 
hour at 100,000 x g, each layer was harvested and diluted in PBS, and centrifuged again at 
100,000 x g overnight. The resulting pellets were then lysed in SDS buffer and probed for the 
presence of FasL by immunoblot as in Figure 3-1A. FasL protein was detected only the fraction 
with a density of 1.16 g/mL (Figure 3-2B), a density indicative of exosomes [167]. Taken 




Figure 3-2: LCLs secrete exosomes containing FasL and MHC class II. 
(A) Cell lysates and spontaneously-secreted exosomes were collected from four LCLs (lines 
E, P, 2, and 4) and probed for the presence of FasL and HLA-DR by immunoblot. (B) Exosomes 
from a representative LCL were floated onto a discontinuous density gradient of iodixanol 
solution and spun for 1 hour at 100,000 x g. Individual layers were removed and diluted with 
PBS, followed by an overnight centrifugation at 100,000 x g. The resulting pellets were lysed 
with SDS buffer and probed for FasL by immunoblot. 
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Double-positive FasL+MHCII+ exosomes are present among LCL-derived exosomes 
Our previous experiments demonstrated that both FasL and MHCII protein were present in 
exosomes secreted by LCLs. While both proteins are present on exosomes, it is not clear from 
these data whether individual exosomes possess both FasL and MHCII (FasL+MHCII+), or 
whether FasL and MHCII are present on distinct subsets of exosomes. Exosomes are too small 
to be accurately detected by flow cytometry, and so must be linked in aggregate to larger 
beads for flow cytometric analysis. We therefore developed an assay to capture exosomes on 
an antibody-coated bead and stain the captured exosomes with fluorescently-conjugated 
antibodies (Figure 3-3). Polystyrene beads coated with streptavidin were incubated with a 
biotinylated antibody and washed several times. Antibody-coated beads were then incubated 
with exosomes, and after washing away excess exosomes, those bound to the beads were 
stained with anti-FasL (Figure 3-3). 
To test for the co-localization of MHCII and FasL into the same exosomes, we harvested 
exosomes from unstimulated and PMA/ionomycin-stimulated LCL culture supernatants and 
concentrated them by centrifugation. Exosomes were then incubated with beads coated with 
anti-MHCII antibody, and stained for various markers.  As can be seen in Figure 3-4A, exosomes 
bound to anti-MHCII-coated beads stained positive for the presence of FasL, suggesting that 
FasL and MHCII are found on the same LCL-derived exosomes. Stimulation with 
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PMA/ionomycin increased the amount of FasL detected on MHCII+ exosomes in both LCLs 
tested (Figure 3-4A). Cells from these experiments were also lysed and probed for FasL and, 
and both cell lines increased FasL production in response to PMA/ionomycin stimulation 
MHCII (Figure 3-4B). Therefore, LCLs secrete MHCII+FasL+ exosomes, and both the production of 








Figure 3-3: Diagram of exosome-bead capture experiments. 
 Exosomes are too small to be accurately detected by flow cytometers, and so must be linked 
in aggregate to larger beads for flow cytometric analysis. Polystyrene beads coated with 
streptavidin were incubated with biotin-conjugated anti-HLA-DR or an isotype control 
antibody. Beads were then washed and incubated with gentle agitation for several hours 
with LCL-derived exosomes. Beads were washed and stained with PE-conjugated anti-FasL 




Figure 3-4: LCLs secrete MHCII+FasL+ exosomes. 
(A) Two LCLs were placed into fresh exosome-free media in the presence or absence of 
PMA/ionomycin. After 5 hours (top panels) or 24 hours (bottom panels), exosomes were 
isolated from culture supernatants as described in the materials section. Purified exosomes 
were then incubated with anti-HLA-DR-coated beads as described in Figure 3-3. Beads were 
washed and stained with either anti-FasL or an isotype control antibody. Beads coated with 
an appropriate isotype control antibody did not display any FasL staining (data not shown).  




LCL-derived exosomes can induce apoptosis in autologous CD4+ T cells 
As LCL-derived exosomes contained MHCII+FasL+ exosomes, we hypothesized that activated 
CD4+ T cells would be susceptible to exosome-induced apoptosis. To test this hypothesis, we 
obtained peripheral blood mononuclear cells (PBMCs) from a donor from whom we had 
previously made an LCL. Using autologous T cells prevents the induction of allogeneic 
interactions between the LCL-derived exosomes and the CD4+ T cells of the donor. LCL-derived 
exosomes were isolated from unstimulated LCL culture supernatant as described above and 
cultured with fresh CD4+ T cells in the presence or absence of super-antigen (SEA). After six 
days in culture, we assessed apoptosis in CD4+ T cells by Annexin-V/propidium iodide staining. 
In the absence of SEA, LCL-derived exosomes produced a modest increase in apoptosis in CD4+ 
T cells (Figure 3-5). In contrast, in the presence of SEA exosomes induced significant levels of 
apoptosis in CD4+ T cells (Figure 3-5). Similar results were obtained using an LCL and CD4+ T 
cells from a second independent donor (data not shown). As SEA facilitates interaction 
between MHCII molecules on exosomes and the TCR on a subset of CD4+ T cells, this suggests 
that LCL-derived exosomes can mediate antigen-specific killing of CD4+ T cells. 
T cells specific for a nominal antigen are rare among peripheral CD4+ T cells, and therefore 
testing the capacity of LCL-derived exosomes to induce antigen-specific apoptosis requires 
prior activation to enrich for antigen-specific T cells. We obtained PBMCs from a healthy 
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subject who had recently received a scheduled booster vaccination against tetanus. PBMCs 
from this donor were cultured with an immunodominant peptide of tetanus toxoid (TT) to 
enrich the CD4+ T cell pool for cell specific to this antigen. After 12 days in culture, CD4+ T cells 
were isolated by negative selection and incubated overnight with autologous LCL-derived 
exosomes in the presence or absence of the TT peptide. Apoptosis was assessed by Annexin-
V/propidium iodide staining among activated T cells (CD4+CD62L-). LCL-derived exosomes in 
the presence of TT peptide induced significant levels of apoptosis in CD4+ CD62L- T cells (Figure 
3-6).  While exosomes in absence of TT peptide also induced apoptosis above baseline, this 
difference did not reach significance (Figure 3-6). Similarly, the addition of a blocking anti-
FasL antibody to culture with exosomes and TT peptide inhibited exosome-induced apoptosis, 
but again this difference did not reach statistical significance. (Figure 3-6). Taken together, 
these data suggest that LCL-derived exosomes can induce antigen-specific apoptosis in 




Figure 3-5: LCL-derived exosomes can induce apoptosis in autologous CD4+ T cells. 
CD4+ T cells were harvested from a repeat donor from whom we had previously generated 
an LCL. CD4+ T cells were incubated with exosomes in the presence or absence of super-
antigen (SEA). After 6 days in culture PBMCs were harvested, and apoptosis was assessed in 
CD4+ T cells by Annexin-V/propidium iodide staining. Data are representative of at least 3 
independent experiments using two distinct donors. 
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Figure 3-6: Antigen-specific killing with TT peptide. 
Peripheral blood mononuclear cells were harvested from a repeat donor from whom we had 
previously generated an LCL. This donor had received a scheduled vaccination against 
tetanus less than one month prior. PBMCs were cultured in the presence of an 
immunodominant peptide of the tetanus toxoid for 12 days. CD4+ T cells were then isolated 
by negative selection and cultured overnight with or without autologous LCL-derived 
exosomes and in the presence or absence of the tetanus toxoid peptide. Apoptosis in 
activated CD4+CD62L- T cells was assessed by Annexin-V/propidium iodide staining. *p<0.05 
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IgM+FasL+ exosomes can be isolated from splenic tissue homogenates  
The previous experiments demonstrate that B cell-derived cell lines can produce FasL+ 
exosomes, but whether this occurs in vivo is still an open question. Exosomes containing FasL 
are present but rare in human plasma under normal conditions[198, 199]. We therefore 
returned to the mouse to look for endogenous B cell-derived exosomes containing FasL. To 
assay for the presence of FasL+ exosomes generated by splenic B cells, we harvested spleens 
from HLA-DR4-transgenic mice.  Spleens were disrupted in PBS, and cells and cellular debris 
were removed by centrifugation.  The exosome fraction was obtained by centrifugation of the 
remaining supernatant at 100,000 x g.  Exosomes were then incubated with beads coated with 
antibodies for B cell-specific markers based on the hypothesis that B cell-derived exosomes 
may have B cell-specific molecules.  These exosome-coated beads were than assayed for FasL 
by flow cytometry.  As seen in Figure 3-7, no FasL was detected on beads coated with anti-
CD19, but FasL was detected on beads coated with anti-IgM.  This result suggests that IgM+FasL+ 
exosomes exist in the spleen, and based on the presence of IgM are likely to be B cell-derived.  
No MHCII was detected on either of the beads (data not shown).  Although there are important 
caveats to these results, takent together they suggest that IgM+FasL+ exosomes produced by B 




Figure 3-7: IgM+FasL+ exosomes can be isolated from splenic tissue homogenates. 
Spleens from wild-type naïve mice were removed, disrupted in PBS, and passed through a 
cell strainer. Splenocytes and large debris were then removed by centrifugation at 500 x g 
and 10,000 x g, respectively. The resulting supernatant was centrifuged at 100,000 x g for 4 
hours and diluted with PBS prior to a second spin at 100,000 x g. Exosomal pellets were then 
re-suspended in PBS and incubated with beads coated with anti-CD19, anti-IgM, or an 
isotype control antibody. Exosome-coated beads were stained with anti-FasL or an isotype 
control antibody and staining was quantified by flow cytometry. Isotype staining is depicted 




A high frequency of LCLs express FasL 
B cells expressing FasL are relatively infrequent under most conditions, and we therefore 
assumed at the outset of this project that FasL expression among B cell-derived cell lines would 
be rare as well. While FasL expression was indeed infrequent among cell lines derived from B 
cell cancers, we found that FasL protein was present in cell lysates from all lymphoblastoid cell 
lines tested in this study. This result was somewhat surprising as LCLs are reportedly 
susceptible to FasL-induced apoptosis, and LCLs have been used extensively as APCs for 
activating T cells [200-203]. These conflicting results can be explained in part by the fact that 
unlike endogenous FasL+ B cells in mice, FasL protein is undetectable on the surface of LCLs. 
Therefore, although LCLs produce FasL, this intracellular sequestration makes it unavailable 
for inducing apoptosis in target cells. 
Lymphoblastoid cell lines are generated by infection with the Epstein-Barr virus, a γ-1 
herpesvirus with oncogenic properties in humans [204].  The virus persists in most infected 
individuals in latently-infected circulating memory B cells [205, 206].Greater than 90% of 
adults are infected with EBV, and although clinical manifestations of infection are generally 
rare, the transforming properties of the virus can lead to B cell-derived malignancies such as 
Burkitt’s and Hodgkin lymphomas [207, 208]. LCLs generated by infection with EBV maintain a 
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latent viral growth program, expressing at least 8 proteins from the viral genome [207]. Among 
these proteins is latent membrane protein 1 (LMP1), a functional mimic of CD40 [209]. 
Signaling of LMP1 differs from that mediated by CD40, as LMP1 signaling is constitutive rather 
than ligand-dependent. Therefore LCLs are essentially in a state of constant CD40 stimulation. 
We previously observed that mouse B cells stimulated with CD40L express higher levels of FasL 
(Chapter 2), and therefore the CD40-mimicry of LMP1 might potentially explain the 
constitutive production of FasL in LCLs. As mentioned previously, stimulation with CD40L has 
been reported to induce FasL expression in other types of cells as well [187-189].  
While most people are first exposed to EBV in infancy, those infected later in life can develop 
acute infectious mononucleosis (AIM) [210]. At the height of acute infection, T cells are 
susceptible to Fas-mediated apoptosis, and in vitro infection of PBMCs with EBV leads to 
elevated levels of FasL on the surface of B cells [142]. Inducing surface expression of FasL in B 
cells may therefore be a means of immune evasion employed by EBV during the lytic cycle 
[211]. Importantly, FasL localization appears to differ between the lytic and latent cycles, as 
FasL in LCLs is intracellular whereas FasL can be found on the surface of B cells during acute 
infection [142]. As the virus transitions into a latent state and settles into homeostasis with the 
host immune system, infected B cells may maintain FasL production but cease transporting it 
to the cell surface. 
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LCLs produce MHCII+FasL+ exosomes 
Immunosuppressive exosomes are an emerging concept with potentially immense utility for 
immunotherapy. Exosomes produced by dendritic cells genetically modified to produce FasL 
suppressed induction of collagen-induced arthritis at least as efficiently as intact FasL-
expressing dendritic cells [170]. Endogenous MHCII+FasL+ exosomes isolated from murine 
plasma have immunosuppressive properties, and were able to induce acquired tolerance in 
recipient animals upon adoptive transfer [171]. Although apparently more rare than in mice, 
MHCII+FasL+ exosomes have been identified in human plasma as well, and showed FasL-
dependent suppressive activity against CD4+ T cells [199]. For the treatment of human 
autoimmune diseases, exosomes may represent a safer alternative to regulatory cells for 
immunotherapy because the phenotype of exosomes is static, whereas regulatory cells can 
potentially differentiate into effector cells after transfer [212]. Although this technique has 
promise, much further work to better understand the effects of exosome-mediated 
immunotherapy before it can become a viable treatment.  
We demonstrate here that LCLs constitutively produce MHCII+FasL+ exosomes with apoptosis-
inducing activity against CD4+ T cells. Although FasL can be detected in LCL-derived exosomes 
under normal conditions, stimulation with PMA/ionomycin increased both the amount of 
MHCII+FasL+ exosomes secreted and FasL production in LCLs. Additionally, while FasL is 
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abundant in LCL cell lysates, it is relatively difficult to detect in exosomes. These results would 
suggest that although constitutively-produced exosomes have T cell killing activity, enriching 
LCL-derived exosomes for FasL may produce more potent immunosuppressive exosomes.  
Additionally, LCLs may prove useful in identifying biologically relevant stimuli that increase 
release of immunosuppressive exosomes in B cells. Finally, a blocking anti-FasL antibody only 
partially inhibited exosome-mediate apoptosis, suggesting that other molecules capable of 
inducing apoptosis in T cells may be present on or in exosomes.  
IgM+FasL+ exosomes are present in vivo 
Although MHCII+FasL+ exosomes have been identified in both mouse and man, the cells 
responsible for producing these exosomes remain unknown [171]. The surface phenotype of 
exosomes can differ from that of its parent cell, and therefore determining the cellular source 
of exosomes based upon the proteins they contain is not straightforward. Importantly, only a 
subset of surface proteins is also found in the secretory lysosome, and as a result surface 
markers specific for a given cell type might not be present on exosomes produced by those 
cells. In our attempts to find B cell-derived exosomes by antibody-coated bead capture, we 
chose to target potential exosomal proteins produced only by B cells. We found that beads 
coated with anti-IgM were able to bind exosomes with FasL, suggesting that B cell-derived 
FasL+ exosomes are present in the mouse spleen. It is important to note that the specificity of 
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the IgM bound to the bead is unknown, and therefore the possibility remains that FasL+ 
exosomes detected are bound indirectly by the specificity of IgM. Natural IgM antibodies are 
known to bind to phospholipid determinants present on both apoptotic cells and exosomes, 
and so this is an important caveat to these results [113, 213]. 
 
3.5 Future Directions 
How does EBV transformation induce FasL expression in LCLs? 
All LCLs tested in this study robustly produced intracellular FasL, suggesting that the latency 
program of EBV drives production of FasL. The mechanism responsible for this phenomenon 
remains unclear, and is an important remaining question. LCLs express at least 8 proteins from 
the EBV episome, including 6 nuclear antigens and 3 membrane antigens [207].The viral 
protein LMP1 is among these viral proteins, and constitutively mimics the signals produced by 
CD40. This tonic signaling from LMP1 may therefore mediate FasL expression in LCLs, as 
stimulation with CD40L led to an increase in FasL production in mouse B cells. LMP1 is 
essential for both B cell transformation continued proliferation of LCLs, and so testing this 
hypothesis using a LMP1-deficent virus is not feasible [214, 215]. The C-terminal of LMP1 
contains several activating regions which associate with many of the signaling adapters shared 
with CD40, including TNF receptor associated factors (TRAFs) and TNF receptor associated 
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death domain protein (TRADD) [216-218]. B cell lines deficient in several of the TRAF molecules 
exist, and examining these lines for expression of FasL may provide insight into the signaling 
events downstream of both CD40 and LMP1 that induce production of FasL [219]. An important 
difference between FasL production in CD40-stimulated B cells and LCLs is localization, as LCLs 
do not have surface expression of FasL. In this regard, differences in the signaling pathways 
downstream of CD40 and LMP1 may provide mechanistic insight. One such difference is the use 
of TRAF2, as CD40 signaling is largely eliminated by the loss TRAF2, but the effects of LMP1 are 
largely unaffected by TRAF2 deficiency [220, 221]. Signals mediated by TRAF2, therefore, may 
promote the translocation of FasL from intracellular stores to the cell surface. 
Do B cells produce FasL+ exosomes in vivo? 
While we have presented suggestive evidence that B cells produce FasL+ exosomes in vivo, 
much more study is required to definitively demonstrate this phenomenon. MHCII+FasL+ 
exosomes are present in the plasma of mice, and therefore examining the plasma of mice 
genetically deficient in B cells for the presence of MHCII+FasL+ exosomes is a straightforward 
way to test this hypothesis. It is important to note, however, that mice lacking B cells during 
development have other potentially-confounding abnormalities, including decreased numbers 
of thymic and splenic T cells, and impaired organization and development of secondary 
lymphoid organs [15, 222, 223]. Mice transiently depleted of B cells may therefore be a more 
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relevant subject for these experiments. If available, mice with a B cell-specific FasL deficiency 
could be used to test this hypothesis as well. If regulatory B cells are indeed the producers of 
immunosuppressive exosomes, than transgenic animals with increased frequencies of 
regulatory B cells, such CD19-transgenic mice, would be expected to have higher 
concentrations of MHCII+FasL+ plasma exosomes [131].  
Can LCL-derived exosomes be used therapeutically? 
Exosome immunotherapy is an intriguing concept because MHCII+FasL+ exosomes have 
demonstrated permanent and precisely focused suppression of an antigen-specific immune 
response in mouse models [170, 171]. Regulatory cells adoptively transferred can behave 
unpredictably after transfer, or even differentiate into effector cells [212]. Additionally, some 
immunotherapies require transfection with adenoviral vectors that can potentially increase 
the risk of developing cancer in recipients. Exosomes, in contrast, can be isolated reliably and 
are therefore cell-free, and do not alter their phenotype in response to different immunogenic 
stimuli.  
Producing MHCII+FasL+ exosomes to treat an individual with autoimmunity requires that the 
exosomes be MHC matched with the recipient, and the only feasible way to ensure this match 
is to use an individual’s own cells to produce the exosomes. Transformation of B cells with EBV 
is reliable, simple, and does not require cell sorting. The genome of EBV is maintained in 
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proliferating LCLs as a large episome (~167kb), and techniques for engineering recombinant 
EBV are well-established [224, 225]. For autoimmune diseases for which an autoantigen has 
been identified, a recombinant EBV can be produced containing the coding sequence for the 
relevant autoantigen fused to a lysosomal sorting sequence. Proteins containing this sequence 
are actively sorted to the secretory lysosomal compartment where they are processed and 
presented on MHCII molecules [226]. Thus, MHCII+FasL+ exosomes produced by such a LCL 
would present various epitopes of the autoantigen (Figure 3-8). The large size of the viral 
genome allows for the addition of other transgenes as well, such a region containing the FasL 
gene under a strong, ubiquitous promoter to ensure robust production of FasL. The resulting 
exosomes can be harvested under sterile conditions by centrifugation or filtration, and either 
frozen for future use or administered directly to the patient (Figure 3-8). Similar strategies 
could be developed for inducing allogeneic tolerance in transplant recipients as well. 
While there are clear advantages to this technique, some potential limitations are worth 
discussing. First, this therapy would only be effective in the treatment for autoimmune 
diseases for which the autoantigen(s) responsible for activating T cells had been identified. 
Additionally, most autoimmune diseases eventually involve reactivity to multiple antigens, 
and so eliminating the CD4+ T cell response to only a single antigen may not be sufficient to 
abrogate symptoms [82]. It is also important to consider the effects of such a therapy on the 
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ability of the recipient to control latent EBV infections, as greater than 90% of patients are 
likely to harbor endogenous virus, and T cell immunity appears to be crucial for controlling 
this latent infection [227]. While CD8+ T cells among PBMCs are relatively resistant to FasL-
mediated apoptosis, it may still be necessary to reduce MHC class I levels in LCL-derived 
exosomes to prevent them from interacting with CD8+ T cells after transfer. This could be 
accomplished by including a shRNA targeting a gene important for MHC class I expression in 
the recombinant EBV genome, such as transporter associated with antigen processing (TAP) or 
β2 microglobulin [228]. Such a strategy would reduce the amount of MHC class I on exosomes, 
and therefore reduce the likelihood that LCL-derived exosomes would deplete EBV-specific 







Figure 3-8: Engineered LCL-derived killer exosomes. 
Because of its large size, the EBV genome can be engineered to express various recombinant genes. 
Hypothetically, a recombinant virus could be produced that would contain the gene coding for a 
relevant autoantigen linked to a lysosomal sorting sequence. This fusion protein would be sorted to 
the lysosomal compartment where it would be processed for antigen presentation. The engineered 
LCL therefore secretes MHCII+FasL+ exosomes presenting various peptides derived from the 
autoantigen. The engineered virus would be used to transform a patient’s own B cells, and therefore 










4.1 Summary of Findings 
Regulatory lymphocytes play an essential role in maintaining immune homeostasis and self-
tolerance. A subset of B cells expresses the apoptosis-inducing molecule FasL and is thought 
have a role in immune regulation through the killing of autoreactive CD4+ T cells (Figure 1-2). 
This mechanism of immune suppression is unique among regulatory lymphocytes populations 
in that it is both antigen specific and permanent. Despite this, relatively little was known about 
the regulation of FasL+ B cell activity or growth prior to the commencement of this study. The 
experiments presented in the preceding chapters were performed to gain insight into the 
biology of FasL+ B cells, with the ultimate goal of finding molecular targets that could be 
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manipulated pharmaceutically to modulate their activity in patients with a variety of 
inflammatory disorders. 
Various functionally and developmentally distinct subsets of B cells have been identified that 
can be distinguished by differential expression of cell surface markers. To better understand 
how FasL+ B cells relate to other B cell subsets, an extensive phenotypic analysis was 
performed comparing the levels of various surface markers in FasL+ and FasL- B cells (Figure 2-
2). Although the surface phenotype of FasL+ B cells was heterogeneous, these cells were 
enriched in the IgMhighCD5+CD1dhigh B cell subset previously reported to contain a higher 
frequency of B cells producing IL-10 (Figure 2-3). A rare population of B cells expressing IL-10 
was present among FasL+ B cells, but most FasL+ B cells did not produce IL-10 (Figure 2-5).  
An analysis of global gene expression found that genes encoding components of the receptor 
for the cytokine IL-5 were expressed at three-fold higher levels in a B cell population enriched 
for FasL+ B cells, suggesting that IL-5 might be important for the growth or function of these 
cells. Surface expression of the IL-5 receptor was indeed higher on FasL+ B cells than on FasL- B 
cells, and treating B cells with IL-5 and CD40L resulted in the expansion of a population 
enriched for FasL+ B cells (Figures 2-8, 2-9). B cells stimulated with IL-5 and CD40L were potent 
inducers of apoptosis in activated primary CD4+ T cells, and this killing function was antigen 
specific and dependent upon FasL (Figure 2-11). IL-5 also enhanced secretion of the anti-
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inflammatory cytokine IL-10 in B cells stimulated with CD40L (Figure 2-12). Collectively, these 
data identify IL-5 as a novel inducer of regulatory B cell function, capable of inducing or 
enhancing at least two distinct regulatory mechanisms. Another type-2 cytokine, IL-4, had an 
opposing effect on regulatory B cell activity, as B cells treated with IL-4 had reduced killing 
activity and did not increase IL-10 production in response to stimulation with IL-5 (Figure 2-13 
and 2-14). These results demonstrate for the first time an antagonistic relationship between IL-
4 and IL-5 regarding the function of regulatory B cells. 
Although FasL+ B cells are rare in vivo, LCLs derived from human B cells showed robust 
expression of FasL protein (Figure 3-1), suggesting the latency program initiated by EBV in 
transformed B cells drives the production of FasL. Although FasL was not detected on the 
surface of LCLs, both MHCII and FasL were present in exosomes isolated from LCL culture 
supernatant (Figure 3-2). A bead-based exosome capture assay showed that MHCII+FasL+ 
exosomes are present among those secreted by LCLs, suggesting that LCL-derived exosomes 
may be able to induce antigen specific apoptosis in CD4+ T cells (Figure 3-4). This ability was 
confirmed by two independent experimental approaches using autologous T cells, showing for 
the first time that LCLs secrete exosomes capable of antigen-specific immune suppression 
(Figure 3-5 and 3-6). To test for the presence of FasL+ B cell-derived exosomes in vivo, a bead-
based exosome capture assay was used to isolate exosomes containing B cell-specific markers 
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and determine if FasL was present among these B cell-derived exosomes. The results of these 
experiments suggested that IgM+FasL+ exosomes are present in the mouse spleen, and given 
the presence of IgM on these exosomes, they are likely to be derived from B cells. Taken 
together, these results suggest that B cells may be capable of mediating immune suppression 
systemically through the secretion of FasL+ exosomes. 
 
4.2 Future Directions 
Therapeutic potential 
Prior to the commencement of this study, relatively little was known about the regulation of 
killer B cell activity and growth. The experiments presented in chapter 2 identified two novel 
regulators of FasL+ B cells. The cytokine IL-5 increased both the killing function and secretion 
of IL-10 in B cells (Figure 2-11, 2-12). Additionally, it has been reported that IL-5 increases 
secretion of anti-inflammatory natural antibodies in B cells [117, 229]. Therefore, targeting 
pathways downstream of the IL-5 receptor may lead to powerful therapeutics that modulate 
multiple immunosuppressive mechanisms of regulatory B cells. Drugs that activate pathways 
downstream of the IL-5 receptor could be of potential use in the treatment of inflammatory 
conditions such as autoimmune diseases and in patients receiving tissue or organ transplants 
[80, 230].  
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Inhibiting these pathways may prove therapeutic as well, as the activity of regulatory B cells 
can be detrimental during an immune response to cancer [231, 232].  Additionally, some B cell-
derived cancers express FasL, and this expression is more common in aggressive forms of 
disease [140, 233]. In vitro, some B cell-derived cancers are capable of inducing FasL-mediated 
apoptosis, suggesting that FasL expression by B cell-derived cancer may be a mechanism for 
inhibiting cancer-specific immune responses [140]. In multiple myeloma, FasL expression 
increases at later stages of disease, and is associated with more severe anemia and bone 
erosion [234]. These more severe complications are thought to be due in part to FasL-mediated 
apoptosis of erthyroblasts and osteoblasts, respectively [234]. Drugs that inhibit pathways 
downstream of the IL-5 receptor may therefore have two mechanisms of action in cancer – 
reducing the detrimental activity of non-transformed regulatory B cells, and inhibiting FasL 
expression in B cell-derived cancer cells. Much further work is required, however, to identify 
specific molecular targets and develop appropriate drugs to modulate their activities. 
As demonstrated in chapter 2, IL-4 treatment of B cells severely inhibited the regulatory 
function of B cells, although it is not yet clear how this effect is mediated (Figure 2-11 and 2-
12). Increasing the activity of the pathways downstream of the IL-4 receptor may therefore 
also be therapeutically relevant in the treatment of cancers derived from B cells. Identifying 
the precise molecular mediators in these pathways is an important next step toward realizing 
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this therapeutic potential. It should be noted that IL-4 has wide-ranging effects on many types 
of cells, including T cells and conventional B cells [235]. Additionally, a TH2-polarized immune 
response is thought to promote tumor growth in some contexts, whereas a TH1-polarized 
response is often associated with tumor rejection [236]. It will therefore be especially 
important to find a molecular target that is specific to B cells for this strategy to work 
therapeutically. 
In chapter 3, data were presented demonstrating that a high frequency of human B cells 
transformed into LCLs by EBV constitutively produce FasL protein (Figure 3-1). Additionally, 
all LCLs tested in this study produced MHCII+FasL+ exosomes that were capable of inducing 
apoptosis in CD4+ T cells (Figure 3-5, 3-6). Other groups have reported that administering 
MHCII+FasL+ exosomes to mice results in long-lived antigen specific tolerance [170, 171]. 
Generating LCLs from peripheral blood B cells is a widely-practiced and relatively simple 
process, requiring only minimal laboratory labor and reagents. Therefore, LCL-derived 
exosomes are a potential source of MHC-matched immunosuppressive exosomes that could 
realistically be used therapeutically in humans. Much further work is required for this to 
become a reality, however. An essential first step would be to test the efficacy and toxicity of 
LCL-derived exosomes in a mouse model. One difficulty in performing these experiments is 
that LCLs cannot be produced from mouse B cells. Alternatively, using humanized mice that 
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express a single common human MHCII protein, such as HLA-DR4, could be used for these 
experiments. Because HLA-DR4 is a common haplotype, obtaining an LCL from an individual 
homozygous for this haplotype would not be prohibitive. Experiments could then be 
performed by injecting HLA-DR4-transgenic mice with LCL-derived exosomes from an HLA-
DR4+ LCL, taking advantage of the ability of human FasL to signal through mouse Fas [243]. 
Using such an experimental system, it would be possible to directly test the 
immunosuppressive qualities of LCL-derived exosomes in vivo, and techniques for improving 
their efficacy could be optimized prior to clinical trials. Although this therapeutic strategy is 
unorthodox and requires further research, its potential as a safer and more effective 
alternative to cellular immunotherapy make it worth pursuing. 
The role of FasL+ B cells in the immune system 
The work presented in this dissertation was performed under the hypothesis that the role of 
FasL+ B cells in vivo is to kill autoreactive CD4+ T cells and thereby help to maintain self-
tolerance (Figure 1-2). In support of this hypothesis, FasL+ B cells generated by stimulation 
with CD40L and IL-5 were potent inducers of apoptosis in activated T cells in vitro, and this 
killing activity was greatly increased upon the addition of the relevant T cell antigen to culture 
(Figure 2-11). Although these in vitro data show that FasL+ B cells have the potential to kill CD4+ 
T cells, it has not been definitively shown that this occurs in vivo. It is therefore prudent to 
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consider the possibility that FasL+ B cells may have functions other than maintaining self-
tolerance.  
Among these alternative functions could be the control of cell populations other than CD4+ T 
cells. In humans, neutrophils are present in the marginal zone of the spleen and interact with 
MZ B cells [237]. As FasL+ B cells are phenotypically similar to MZ B cells (Figure 2-2), it is 
possible that FasL+ B cells reside in the marginal zone where they could interact with Fas-
susceptible neutrophils [238]. In this context, the function of FasL+ B cells may be to prevent 
neutrophils from entering other compartments of the spleen, or to prevent the production of 
neutrophil extracellular traps by ensuring that neutrophils undergo apoptosis instead. 
Another potential function of FasL+ B cells is the direct killing of malignant cells, as some types 
of cancers are susceptible to apoptosis induced by death ligands such as FasL [239]. Infiltrating 
B cells can be found in many types of tumors, although presently their function at these sites is 
not known [240]. Finally, although the most well-known consequence of Fas signaling is cell 
death, there are reports of Fas signaling mediating activation rather than apoptosis [241, 242]. 
The effects of Fas signaling appear to differ depending upon the context in which the signal is 
received, and therefore FasL+ B cells may serve to activate T cells under certain conditions 
rather than kill them.  
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These alternative functions are not mutually exclusive, and it remains possible that FasL+ B 
cells can have different functions in different immunological contexts. Given the phenotypic 
heterogeneity displayed by FasL+ B cells (Figure 2-2), this population may indeed be comprised 
of distinct subsets with differing functional roles or cellular targets. Further work is required 
to determine the true function(s) of FasL+ B cells in vivo, and many of these potential roles 
could be investigated using mice genetically deficient in FasL in B cells only. Such mice have 
not been systemically investigated, and should be the subject of future studies. 
 
4.3 Concluding Remarks 
The work described in this dissertation sought to provide novel insights into the regulation 
and function of FasL+ killer B cells, a potentially important regulatory B cell population. The 
results of these experiments have identified biologically relevant stimuli that positively and 
negatively regulate the activity of FasL+ B cells. The molecular mediators downstream of these 
stimuli are novel targets for pharmaceutical intervention in a variety of disorders, including 
autoimmune diseases and cancer. Additionally, this work describes for the first time the 
production of immunosuppressive exosomes by B cells. The use of B cell-derived exosomes for 
immunotherapy as described herein is a novel concept, and has several advantages over cell-
based immunotherapy. These experiments have therefore set the groundwork for future 
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